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Dinucleoside polyphosphates comprises a group of dinucleotides formed by two nucleosides linked by a
variable number of phosphates, abbreviated NpnN (where n represents the number of phosphates).
These compounds are naturally occurring substances present in tears, aqueous humour and in the retina.
As the consequence of their presence, these dinucleotides contribute to many ocular physiological
processes. On the ocular surface, dinucleoside polyphosphates can stimulate tear secretion, mucin
release from goblet cells and they help epithelial wound healing by accelerating cell migration rate.
These dinucleotides can also stimulate the presence of proteins known to protect the ocular surface
against microorganisms, such as lysozyme and lactoferrin. One of the latest discoveries is the ability of
some dinucleotides to facilitate the paracellular way on the cornea, therefore allowing the delivery of
compounds, such as antiglaucomatous ones, more easily within the eye. The compound Ap4A has been
described being abnormally elevated in patient's tears suffering of dry eye, Sjogren syndrome, congenital
aniridia, or after refractive surgery, suggesting this molecule as biomarker for dry eye condition. At the
intraocular level, some diadenosine polyphosphates are abnormally elevated in glaucoma patients, and
this can be related to the stimulation of a P2Y2 receptor that increases the chloride efﬂux and water
movement in the ciliary epithelium. In the retina, the dinucleotide dCp4U, has been proven to be useful to
help in the recovery of retinal detachments. Altogether, dinucleoside polyphosphates are a group of
compounds which present relevant physiological actions but which also can perform promising thera-
peutic beneﬁts.
© 2016 Elsevier Ltd. All rights reserved.Contents
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Fig. 1. Chemical structure of dinucleoside polyphosphates. The top panel shows the
molecular structure of diadenosine tetraphosphate (Ap4A). The middle and bottom
ﬁgures shows two synthetic dinucleoside polyphosphates relevant in ocular physio-
logical processes, diuridine polyphosphate (Up4U in the middle) and uridine deoxy-
cytidine tetraphosphate (dCp4U, below).1. Introduction
1.1. Dinucleoside polyphosphates: structure and features
Dinucleoside polyphosphates are a family of dinucleotides
related to others such as nicotinamide adenine dinucleotides (NAD
and NADP), but slightly different in their structure. Dinucleoside
polyphosphates comprise all those dinucleotides formed by two
nucleosides bridged by a variable number of phosphates. The two
nucleosides moiety can be formed by ribose which may present the
same or different bases, either purines or pyrimidines (Fig. 1).
Although in theory the possibilities of dinucleotides are enormous,
simply by combining the nitrogenised bases and the phosphate
length, there are only a few which have been recognised as natu-
rally occurring dinucleoside polyphosphates, nonetheless, other
dinucleoside polyphosphates have been synthesised either enzy-
matically or chemically (Guranowski et al., 1995; Mizuno and
Sasaki, 1965; Ortiz et al., 1993). Dinucleoside polyphosphates can
be named in different ways, for instance, a, u dinucleoside poly-
phosphates, dinucleoside 50, 5000-P1, Pn polyphosphates or NpnN. The
latter is the most common one in which “N” is substituted by the
bases (A, G, U, for example) and “n” by the number of phosphates.
Dinucleoside polyphosphates found in biological systems are
those formed by two adenosines, which are termed diadenosine
polyphosphates, ApnA, the ones formed by guanosines, diguano-
sine polyphosphates, GpnG, or a combination of both, one moiety
with adenosine and the other with guanosine (GpnA). Concerning
the phosphate length linking both nucleosides, this can vary from
two to seven, although the most common are those dinucleotides
with 3e5 phosphates. Common, naturally occurring dinucleoside
polyphosphates, according to the number of phosphates, are Ap5A
or Gp4G.
Synthetic dinucleoside polyphosphates are relevant since they
depict remarkable actions on ocular physiology (Guzman-Aranguez
et al., 2007, 2011). Among these the ones with uridine, diuridine
polyphosphates (like Up4U AKA diquafosol), with deoxycytidine
and uridine (dCp4U, also termed denufosol), or those with hypo-
xanthine, diinosine polyphosphates (IpnI), have demonstratedPlease cite this article in press as: Carracedo, G., et al., The role of dinucleoside polyphosphates on the ocular surface and other eye structures,
Progress in Retinal and Eye Research (2016), http://dx.doi.org/10.1016/j.preteyeres.2016.07.001
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described (Fujihara et al., 2001; Guzman-Aranguez et al., 2012).
The history of dinucleoside polyphosphates started far away
from the future physiological and pharmacological applications
found in the eye. Indeed, the ﬁrst news on these molecules
occurred in the 1960's. Dinucleoside polyphosphates were discov-
ered in the eggs of brine shrimps, mostly diguanosine poly-
phosphates (Finamore and Warner, 1963; Warner, 1964). These
dinucleotides are the basis for the development of the eggs into
proper shrimps since they will be used for DNA synthesis.
It was not until a few years later when it was possible to identify
a biochemical reaction showing the synthesis of a dinucleoside
polyphosphate. Scientists, when investigating the reaction be-
tween aminoacids and their corresponding tRNAs during the pro-
tein synthesis process discovered the presence of some
diadenosine polyphosphates (Randerath et al., 1966; Zamecnik
et al., 1966). Over the following years, most of the efforts were
dedicated to describing their structural and chemical properties,
mainly by spectrometric methods (Bush and Tinoco, 1967; Cheng,
1968; Warshaw and Tinoco, 1965). Changes in the molecules pre-
sent were also studied when environmental properties (Lee et al.,
1979) such as temperature or pH was modiﬁed (Chan and Nelson,
1969; Davis and Tinoco, 1968; Glaubiger et al., 1968; Hruska and
Danyluk, 1968; Ikehara et al., 1970; Rabczenko and Shugar, 1971;
Ts'o et al., 1969). The structural changes are especially relevant
when the pH medium is altered. The structure of a NpnN, for
example, Ap4A, under physiological pH condition (pHz 7), depicts
a stacked conformation inwhich the adenine rings are piled up, this
being possible due to the phosphate chain folding. This is caused by
the negatively charged phosphate groups and the partially posi-
tively charged adenine rings and the consequent electrostatic in-
teractions. A different panorama is observed when the pH lowers
(pH z 4). Under this condition the phosphates are folded but the
adenine rings are pointing to opposite directions. The maximal
open possible conformation is reached at a pH below 3. Under this
condition the protonation of the phosphates occurs and the in-
teractions among the adenines and phosphates do not exist
(Guzman-Aranguez et al., 2011).
The conformational changes observed at different pH, may
explain why these dinucleotides can interact with different puri-
nergic receptors, mainly when in some environmental conditions,
such as acidic synapses (glutamatergic) the conditions can be far
from neutral conditions (Gualix et al., 2003).
Concerning temperature, it seems that dinucleoside poly-
phosphates at low temperatures present their bases in a stacking
conformation being so close to each other that there is no room for
water between them. On the contrary, when temperature is high,
even at denaturing conditions (above 40 C), the bases are not
stacked and they do not interact with each other and therefore can
interact with the solvent and other molecules. In this case, the only
limitation of the aromatic bases would be their covalent bonds to
the respective riboses (Davis and Tinoco, 1968; Glaubiger et al.,
1968).
1.2. Presence and actions of dinucleoside polyphosphates
1.2.1. Presence and intracellular actions of dinucleoside
polyphosphates
It took quite a long time from the moment these dinucleotides
were identiﬁed until some biochemical and physiological actions
for these compoundswere detected. One of the ﬁrst actions was the
effect of diadenosine tetraphosphate, Ap4A, on DNA polymerase
triggering DNA replication (Grummt, 1978, 1979; Grummt et al.,
1979). Indeed, it has been possible to correlate changes (in-
creases) in Ap4A concentrations during the cell cycle and speciallyPlease cite this article in press as: Carracedo, G., et al., The role of dinucle
Progress in Retinal and Eye Research (2016), http://dx.doi.org/10.1016/j.pduring cell proliferation and DNA synthesis (Bambara et al., 1985).
These experiments were quite controversial, although other au-
thors could, in part, conﬁrm the relationship between Ap4A and
DNA synthesis, it seemed that apparently the dinucleotide would
prime DNA synthesis rather than activating the polymerase
(Zamecnik et al., 1982). Also, some other studies suggested a close
relation between the amino acid activation process and DNA
replication in mammalian cells (Grummt, 1983; Rapaport et al.,
1981).
Another intracellular action suggested for dinucleoside poly-
phosphates has been its possible role of “alarmone” (Lee et al.,
1983; Varshavsky, 1983). An alarmone is a molecule that reﬂects
and indicates a stress situation within a cell. A classical situation is
that in which an elevation of temperature, apart from increasing
the levels of heat shock proteins (HSPs), also produces a rise in
dinucleoside polyphosphates such as Ap3A, Ap4A, Gp4A and Gp3A
(Lee et al., 1983). The same dinucleotides are increased when cells
are submitted to oxidative stress in a process independent from the
dinucleotide synthesis by aminoacyl-tRNA synthetases.1.2.2. Presence and extracellular actions of dinucleoside
polyphosphates
Although the presence and actions of dinucleoside poly-
phosphates have been reported in several tissues as indicated
(Andersson,1989; Rapaport and Zamecnik, 1976; Ripoll et al., 1996),
two sources are relevant concerning the eye physiology: the blood
vessels and the nervous system.
Apart from the presence of dinucleoside polyphosphates in
crustaceans as previously indicated, these molecules were found as
putative active vasoactive compounds when they were discovered
in platelet secretory granules (Flodgaard and Klenow, 1982; Luthje
and Ogilvie, 1983). From the moment they were discovered the
main interest of the scientiﬁc community was to identify those
actions triggered by the dinucleotides in the blood stream. In this
sense, one of the ﬁrst roles was their involvement in platelet ag-
gregation. Interestingly, the two dinucleotides contained in the
platelets (in their dense granules), Ap3A and Ap4A, depicted
opposite actions; while the ﬁrst was inducing platelet aggregation,
the second, showed disaggregating properties (Luthje et al., 1985).
Nonetheless, the existence of dinucleoside polyphosphates in the
plasma and blood (Luthje and Ogilvie, 1988), also suggested an
effect on vasoconstriction or/and vasodilation. When analysing the
effect of the vascular tone, dinucleoside polyphosphates such as
Ap4U produces a biphasic effect although the predominant one at
low concentrations is vasoconstriction, infusions of this dinucleo-
tide elicit hypotension and electrolyte retention (Flores et al., 1999;
Hansen et al., 2010).
The identiﬁcation of dinucleoside polyphosphates and mainly
diadenosine polyphosphates in neural secretory vesicles showed
the storage of these dinucleotides with classical transmitters such
as noradrenalin (Rodriguez del Castillo et al., 1988). This co-
localization was further extended to cholinergic and mono-
aminergic synaptic vesicles (Miras-Portugal et al., 1998, 1999;
Pintor et al., 1992). Moreover, it was possible to demonstrate that
these dinucleotides were releasable in a Ca2þ dependent manner
from brain synaptic terminals (Pintor et al., 1991, 1992) and also by
the effect of drugs such as amphetamines (Pintor et al., 1993). The
role of diadenosine polyphosphates, mainly Ap4A and Ap5A in the
nervous system has been the modulation of the release of mono-
amines (Giraldez et al., 2001), glutamate (Gualix et al., 2003), or the
inhibition of synaptic transmission in the hippocampus (Klishin
et al., 1994).oside polyphosphates on the ocular surface and other eye structures,
reteyeres.2016.07.001
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Extracellular actions of dinucleoside polyphosphates occurred
by means of receptors on the cell surface termed P2 purinergic
receptors. These types of receptors are divided into two families,
the P2X ionotropic (Habermacher et al., 2015) and the P2Y
metabotropic receptors (von Kugelgen and Harden, 2011).
P2X receptors are activated by nucleotides and dinucleotides
which mediate the rapid and non-selective cation transients
(mainly Naþ and Ca2þ) from the extracellular space (Samways et al.,
2014), causing depolarization of the membrane ion channels and
subsequent activation of voltage dependent calcium channels.
Seven members of P2X receptors in mammalians have been cloned
(P2X1-P2X7) and they combined various forms of these subunits
(Saul et al., 2013). Cloning of P2X receptors has revealed that all the
subunits have large extracellular loop with ten cysteine residues,
two transmembrane domains and short intracellular C and N ter-
minals (Roberts et al., 2006). Three subunits are necessary to form a
functional native channel, and these channels are organized as
homotrimers or heterotrimers (Coddou et al., 2011).
P2Y receptors are metabotropic receptors, members of the
family of G protein-coupled receptors containing seven hydro-
phobic transmembrane domains connected by three extracellular
loops and three intracellular loops, with an extracellular N-termi-
nal end and another C-terminal oriented intracellularly (Jacobson
and Boeynaems, 2010). These receptors are coupled, via G pro-
teins to others, such as phospholipase C (PLC), adenylate cyclase or
to ion channels (von Kugelgen and Hoffmann, 2015). To date, the
P2Y family comprises eight members (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11,
P2Y12, P2Y13 and P2Y14) encoded by different genes. They can beCiliary process Physiological processes
Agonists of P2Y6 Decrease of IOP
Antagonists of P2Y2 Decrease of IOP
Cornea Physiological processes
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Fig. 2. Physiological processes mediated by purinergic receptors in the eye. Picture shows
by activation or blockage of purinergic receptors and their therapeutic potential in certain
Please cite this article in press as: Carracedo, G., et al., The role of dinucle
Progress in Retinal and Eye Research (2016), http://dx.doi.org/10.1016/j.porganized into two groups based on their speciﬁc G protein
coupling. In one group, that includes the P2Y1, P2Y2, P2Y4, P2Y6 and
P2Y11 receptors, are all coupled to Gq and the further activation of
phospholipase C b, with the consequent formation of inositol
triphosphate (IP3) and the mobilization of intracellular Ca2þ. The
other group includes the P2Y12, P2Y13 and P2Y14 receptors, asso-
ciated with Gi proteins and inhibiting adenylate cyclase. The P2Y11
is the only thing that can be coupled to both Gs and Gq proteins
(Jacobson et al., 2015).
Concerning the action of dinucleoside polyphosphates and the
activation of P2 receptors, most of the research has been carried out
for ApnA compounds (Hoyle et al., 2001). In this sense, diadenosine
polyphosphates can activate all the P2X receptors (Wildman et al.,
1999), including the heteromeric P2X2/3. It is noteworthy to indi-
cate that the most active dinucleotide has been Ap4A in most cases.
(Pintor and Miras-Portugal, 1995b). Also, the P2X7 was only sen-
sitive to these dinucleotides at concentrations above 1 mM, this
effect being far from the physiological concentrations of these
compounds.
Regarding the P2Y receptors, P2Y1 and P2Y2 are the ones that
are stimulated by diadenosine polyphosphates (Patel et al., 2001).
The tandem Ap4A-P2Y2 is of special interest since it participates in
many physiological processes in many ocular structures (Fig. 2 see
below).
1.4. Dinucleoside polyphosphate degradation
The concentration of dinucleoside polyphosphates is tightly
regulated by a variety of enzymes, mainly hydrolases that are
present in all organisms and generally act on the polyphosphatesnjunctiva Physiological processes
onists of P2Y2 Stimulate tear secretion
etinal pigment 
pithelium (RPE) Physiological processes
gonists of P2Y2
Stimulate subretinal fluid reabsorption 
in retinal detachment
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inflammation
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üller cells
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a schematic representation of the eye and the main physiological processes performed
eye pathologies.
oside polyphosphates on the ocular surface and other eye structures,
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of dinucleoside polyphosphates have been reviewed by Gur-
anowski (Guranowski, 2000).
Extracellular dinucleotides, which regulate physiological pro-
cesses via P2 receptors activation, are degraded principally by ecto-
nucleotide pyrophosphatase/phosphodiesterases (NPPs) (Asensio
et al., 2007; Vollmayer et al., 2003). This family of enzymes are
hydrolases located on cell surface and are a type of the so called
ecto-nucleotidases (Zimmermann et al., 2012). In vertebrates, NPPs
have seven members (NPP1eNPP7) but only three (NPP1eNPP3)
can degrade nucleotides (dinucleotides but also nucleoside tri-
phosphates and diphosphates) (Goding et al., 1998; Jin-Hua et al.,
1997; Stefan et al., 1999). Dinucleotides degradation by NPPs pro-
duce nucleoside monophosphates (NMP) plus nucleoside poly-
phosphates (NPn1). Therefore, NPPs can generate metabolites
biologically active such as ADP and ATP that are obtained from the
naturally occurring diadenosine polyphosphates (Vollmayer et al.,
2003; Zimmermann, 2000). These nucleotides can also be
degraded by NPPs and essentially through ecto-nucleoside
triphosphate diphosphohydrolases (NTPDases), other family of
ecto-enzymes that can degrade nucleoside triphosphates and di-
phosphates (Zimmermann, 1999).
On the other hand, the degradation of diadenosine poly-
phosphates and their metabolites ATP as well as ADP produce AMP.
This nucleoside monophosphate can also be catabolized through
ecto-50-nucleotidase (eN) as well as alkaline phosphatase enzymes
(this last ecto-nucleotidasemay also act on ATP and ADPmolecules)
(Zimmermann et al., 2012). Consequently, AMP is converted into
the nucleoside adenosine, which mediates purinergic effects via P1
receptors interaction (Jacobson and Gao, 2006).
Finally, extracellular adenosine can be eliminated from the
synaptic cleft through cell surface adenosine deaminases that
convert adenosine to inosine and/or nucleoside transporters
(Bonan, 2012; Franco et al., 1997; Pastor-Anglada and Perez-Torras,
2015). These transporters, equilibrative and concentrative nucleo-
side transporters, are integral membrane proteins implicated in the
cellular uptake of adenosine (Bonan, 2012; Pastor-Anglada and
Perez-Torras, 2015).
2. Dinucleoside polyphosphates in the eye
2.1. Ocular surface
The ocular surface is the outer zone of the eye. It is a functional
unit composed of different structures such as corneal and
conjunctival epithelium, lacrymal glands, eyelids and tear ﬁlm. All
components of this functional unit are linked through the inner-
vation and vascular immunologic and endocrine systems. The main
functions of the ocular surface are to maintain the transparency of
the cornea (optic quality issues) and to hydrate and protect the
corneal and conjunctival epithelium to the external agents. The tear
ﬁlm is mainly in charge of these functions. It is critical to have a
correct volume and stability of the tear ﬁlm to maintain the
integrity of the ocular surface. The loss of the ocular homeostasis
provokes serious clinical manifestations as a dry eye, infections of
epithelial defects (Gipson, 2007; Knop and Knop, 2007; Paulsen,
2008).
The ocular structure that has probably been investigated in
more depth regarding dinucleoside polyphosphates is the ocular
surface and specially the tear ﬁlm. The presence of diadenosine
polyphosphates in the tear ﬁlm has been noted in different con-
ditions and also the different purinergic receptors in the ocular
surface that can be activated by the dinucleotides (Guzman-
Aranguez and Pintor, 2012). Moreover, the effects of the ocular
surface of different dinucleotides when these compounds arePlease cite this article in press as: Carracedo, G., et al., The role of dinucle
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(Crooke et al., 2008). In the following sections, the presence and
effect of dinucleoside polyphosphates will be reviewed.
2.1.1. Purinergic receptors in the ocular surface
P2X and P2Y receptors are expressed in different zones of the
ocular surface, the P2Y2 subtype being the most abundant, identi-
ﬁed in the corneal and conjunctival epithelium, corneal endothe-
lium and main lacrimal gland (Pintor et al., 2004b). All P2
purinergic receptors described in the ocular surface and their
functions are summarized in Table 1. The expression of P2 receptors
in different ocular surface locations suggests the involvement of
these receptors in the physiology of the eye (Guzman-Aranguez
and Pintor, 2012). In fact, during the last decade, the role of
several nucleotides and their receptors in ocular processes,
including tear secretion (through P2Y2 receptor) (Jumblatt and
Jumblatt, 1998; Murakami et al., 2000), corneal wound healing
(P2Y2 is able to accelerate the corneal re-epithelization and pro-
liferation, meanwhile P2Y6 inhibits the process) (Byun et al., 2016;
Crooke et al., 2009; Mediero et al., 2006), and corneal epithelial
migration and stromal organization (mediated through P2X7 re-
ceptor) have been described (Mankus et al., 2012; Mayo et al.,
2008).
2.1.2. Action of ectodinucleotidases in the ocular surface
As we mentioned above, the dinucleotides effects on ocular
surface are due mainly to Ap4A and Ap5A but also their metabolites
such as ATP and adenosine and the ecto-nucleotidases, mainly
NPPs, control the availability of these extracellular dinucleotides
and their metabolites. In this context, the expression of some ecto-
enzymes has been detected, including ENPP1 as well as ENPP3
isoforms, NTPD1 isoform and 5NTE in human conjunctival cells
obtained by impression cytology (see Fig. 3). Regarding adenosine,
ocular surface also present ecto-adenosine deaminases and nucle-
oside transporters that can control its possible effects (Majumdar
et al., 2003; O'Brien et al., 1987).
The existence of conjunctival NPP isoenzymes (Fig. 3) with
different substrate speciﬁcity might explain, together with the non-
neuronal origin of Ap4A and Ap5A, the different concentration of
these dinucleotides in tear. Nevertheless, Vollmayer and colleagues
have proved that NPP1 and NPP3 hydrolyze Ap4A as well as Ap5A
with similar rates (Vollmayer et al., 2003).
2.1.3. Presence in the tear ﬁlm of healthy patients
The presence of diadenosine polyphosphates in the tear ﬁlm
was studied due to their properties to enhance both tear secretion
and to increase the wound healing rate (Guzman-Aranguez et al.,
2007, 2011; Pintor et al., 2004a; Pintor et al., 2002b). The exoge-
nous addition of these dinucleotides suggested their presence as
natural constituents of tears.
When investigating dinucleotides in tears, this ﬂuid was
extracted by using paper strips to perform the Schrimer test (for
tear volume measurement), placed in the inferior lid margin of the
eye for 5min (van Bijsterveld,1969). The strips were then processed
to be evaluated by High Pressure Liquid Chromatography (HPLC),
following the procedure described by Pintor et al. (Pintor et al.,
1992). The ﬁrst adenine dinucleotides described in tear were
Ap4A and Ap5A, which were found in New Zealand rabbit tears
(Pintor et al., 2002b). Diadenosine tetraphosphate concentration
was 2.92 ± 0.28 mM and diadenosine pentaphosphate concentra-
tion was 0.587 ± 11 mM. These concentrations would be enough to
activate the ocular surface P2 receptors.
Initially, the hypothesis of the release of these dinucleotides in
rabbit tear ﬁlmwas thought to occur via the exocytotic release from
the nerve terminals present on the ocular surface, since thisoside polyphosphates on the ocular surface and other eye structures,
reteyeres.2016.07.001
Table 1
Purinergic receptors expressed in the ocular surface. Adapted from Guzman-Aranguez et al., 2013.
P2 subtype Species Function References
Corneal Epithelium
P2X5 Rat Undetermined (Groschel-Stewart et al., 1999)
P2X7 Rat, mouse and human Epithelial migration and stroma reorganization (Dutot et al., 2008; Groschel-Stewart et al.,
1999; Mayo et al., 2008)
P2Y1, P2Y4 Rabbit, rat and human Undetermined (Klepeis et al., 2004; Pintor et al., 2004b)
P2Y2 Monkey, rabbit, rat and human Re-epithelization, corneal proliferation and
corneal permeability increasing
(Cowlen et al., 2003; Crooke et al., 2009; Klepeis
et al., 2004; Loma et al., 2015b; Mediero et al.,
2008; Pintor et al., 2004b)
P2Y6 Rabbit, rat and human Re-epithelization delay and corneal
proliferation increasing
(Klepeis et al., 2004; Mediero et al., 2006; Pintor
et al., 2004b)
P2Y11 Rabbit and human Undetermined (Klepeis et al., 2004)
Conjuctival Epithelium
P2X7 Human Membrane permeabilization associated with
iatrogenic pathology
(Dutot et al., 2008)
P2Y2 Monkey, dog, rabbit and human Tear ﬂuid and mucin secretion stimulation (Cowlen et al., 2003; Jumblatt and Jumblatt,
1998; Li et al., 2001; Murakami et al., 2000;
Terakado et al., 2014)
Corneal Endothelium
P2Y1 Bovine Intracellular Ca2þ concentration increasing (Gomes et al., 2005)
P2Y2 Bovine, monkey and rabbit Intracellular Ca2þ concentration increasing (Cowlen et al., 2003; Gomes et al., 2005)
Lacrymal Gland
P2X1, P2X2, P2X4, P2X5, P2X6 Rat Undetermined (Hodges et al., 2009; Kamada et al., 2012)
P2X3, P2X7 Rat Intracellular Ca2þ concentration increasing and
protein secretion
(Hodges et al., 2011; Hodges et al., 2009)
P2Y2, P2Y4, P2Y12, P2Y14 Rat Undetermined (Kamada et al., 2012; Tanioka et al., 2014)
P2Y1, P2Y11, P2Y13 Rat Intracellular Ca2þ concentration increasing (Kamada et al., 2012; Ohtomo et al., 2011)
Meibomian Glands (Eyelid)
P2Y2 Rat and monkey Undetermined (Cowlen et al., 2003; Tanioka et al., 2014)
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central nervous system (Pintor et al., 2002a). However, when the
ocular denervation was performed in rabbits, the release of these
dinucleotides was similar to non-denervated animals, indicating
that the delivery was not from the nerve terminals by a Ca2þ in-
dependent mechanism in the CNS (Guzman-Aranguez et al., 2007).
The mechanism for the dinucleotide release in the ocularM NTPD1 5NTE ENPP1 ENPP3
E.S. (bp) 520 437 410 164
Fig. 3. Presence of ecto-nucleotidases transcripts in human conjunctival epithelial
cells. Agarose gel electrophoresis images of conjunctival NTPD1, eN, NPP1 and NPP3
partial gene transcripts. RT-PCR assays were carried out with total RNA isolated from
conjunctival cells obtained by impression cytology and speciﬁc primers. RT-PCR
products obtained with NTPD1 speciﬁc forward (50-ATGGCAAGGACTACAATG-30) and
reverse (50-GAAAAGCAGTATTCACTCA-30) primers (lane 1, expect amplicon size ¼ 520
bp), using eN speciﬁc forward (50-GATCGAGCCACTCCTCAAA-30) and reverse (50-
GCCCATCATCAGAAGTGAC-30) primers (lane 2, expect amplicon size ¼ 437 bp), using
NPP1 speciﬁc forward (50-GAATTCTTGAGTGGCTACAGCTTCCTA-30) and reverse (50-
CTCTAGAAATGCTGGGTTTGGCTCCCGGCA-30) primers (lane 3, expect amplicon size¼
410 bp) and using NPP3 speciﬁc forward (50-CGACTGCACTATGCCAAGAA-30) and
reverse (50-GGTCCATGTGCCAGAAAGAT-30) primers (lane 4, expect amplicon size ¼ 164
bp); Lane M, 100 bp DNA ladder molecular weight marker.
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presence of diadenosine polyphosphates in the human tear ﬁlm
(Pintor et al., 2002a). The presence of Ap4A and Ap5A was found, as
in rabbit model, and it was possible tomeasure small levels of Ap3A.
In human tears, the levels of diadenosine polyphosphates are
2.1 ± 2.2 nM,108.7 ± 18.3 nM, and 37.1 ± 6.2 nM for Ap3A, Ap4A, and
Ap5A, respectively. The concentrations of diadenosine poly-
phosphates in rabbits were one order of magnitude higher than
that found in humans, but the Ap4A/Ap5A ratio in rabbits and
humans was almost identical, with ratios of 2.97 and 2.91,
respectively.
In addition, ATP seems to be present in tears contributing to the
nucleotide pool present in tears, therefore modulating some
physiological processes on the eye surface. Srinivas and co-workers
found that its presence in tears is a consequence of shear stress
induced on the corneal epithelial cells in cultured rabbit corneal
epithelial cells model (Srinivas et al., 2002). This fact suggested that
other nucleotides such as diadenosine polyphosphates could be
also released in a similar way. Carracedo and co-workers found that
shear stress stimuli induced Ap4A and Ap5A release from human
corneal epithelial cells both In vitro and In Vivo (Carracedo et al.,
2013). The results obtained In vitro were consistent with Srinivas
ﬁndings (Srinivas et al., 2002). Since in the studies performed by
Carracedo, shear stress did not increase the amount of lactate de-
hydrogenase in human, the presence of Ap4A and Ap5A was not a
consequence of cell rupture, although the exact mechanism of
release remains to be determined. Mechanical perturbations such
as cell stretching (Patel et al., 2005), hydrostatic pressure (Cockayne
et al., 2000; Ferguson et al., 1997; Knight and Burnstock, 2001) and
compressive stress (Sauer et al., 2000) seem to be the candidates to
trigger the release of these dinucleotides. The motion of the upper
eyelid during the blinking process seems to be responsible for
exerting shear stress on the epithelial cells and therefore increasing
the levels of both diadenosine polyphosphates, concomitantly with
the increase in the blinking frequency (Carracedo et al., 2013).
Ap4A and Ap5A concentrations in tear ﬁlm of healthy patientsoside polyphosphates on the ocular surface and other eye structures,
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Fig. 5. Sex-related differences in Ap4A and Ap5A concentrations in tear. Upper panel
shows Ap4A concentrations in tear in the whole group and the subgroups of older and
younger than 50 years old. Lower panel shows Ap5A concentrations in tear in the
whole group and the subgroups of older and younger than 50 years old. There are no
differences in dinucleotides levels between genders in any groups (p > 0.05, t-Student
test for independent samples), even so, there is a signiﬁcant increase in Ap4A and Ap5A
concentration groups in subjects older than 50 years in males and females (p < 0.01 in
Ap4A levels and p < 0.05 in Ap5A levels, t-Student test for independent samples).
Values represent means ± SEM.
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(Pintor et al., 2002a). The age is considered one the most relevant
factors to suffer dry eye, this may be due to the reduction in the
lacrimal production or due to the increase in the evaporation rate
associated with aging (Mathers et al., 1996). There are many studies
corroborating this assumption, in spite of the percentage of prev-
alence which is very variable, changing from 5% to 35% at 50 years
old, or 20%e40% at 80 years of age (Moss et al., 2000; Schein et al.,
1997) (Chia et al., 2003; Lee et al., 2002; Lin et al., 2003;
Schaumberg et al., 2003, 2009; Viso et al., 2009), although there
is consensus that the prevalence increases signiﬁcantly after 50
years of age. The other main factor to develop dry eye is gender, it
being more common in women than men. The Beaver Dam study
showed a prevalence of dry eye of 18% in women and only 11% in
men, and some other studies described even higher differences
between women and men (Paulsen et al., 2014). The principal
reason for these differences would be the hormonal factor (Guillon
and Maissa, 2010).
Due to the effect of some dinucleotides on the tear secretion (see
section 2.1.7.), our research group considered it interesting to
evaluate the variations in diadenosine polyphosphates concentra-
tions as a function of aging and gender. Ninety-three healthy sub-
jects were recruited to participate in the study. The age range was
from 7 to 90 years old. Of the total 93 subjects, 47 were men and 46
werewomen, all of themwithout any ocular surface pathology. The
levels of Ap4A and Ap5A were analyzed with and without anes-
thetic, discarding Ap3A due to the low concentration found in a
previously study (Pintor et al., 2002a).
The obtained results showed that Ap4A concentration remained
stable until 50 years old, increasing its concentration signiﬁcantly
from this age (p value < 0.01; one way ANOVA). However, no sig-
niﬁcant changes were found for Ap5A concentration throughout the
age range (p ¼ 0.245, one way ANOVA, Fig. 4). When comparing
Ap4A concentrations in function of gender, it was found that there
wasmore diadenosine tetraphosphate in men tears than inwomen,
but without a statistically signiﬁcant difference (p value ¼ 0.078; t-
Student test for independent samples). For Ap5A, the concentra-
tions were similar in both groups of subjects (p value ¼ 0.761; t-
Student test for independent samples, Fig. 5). As we will see in the
following section, a correlation between the age (dry eye disease
main factor), and Ap4A concentration appears to exist.
2.1.4. Presence in ocular surface pathology
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Fig. 4. Age-related variations in Ap4A and Ap5A concentrations in tear. Graph shows
the signiﬁcant increase on Ap4A levels throughout age (* p < 0.01, one way ANOVA),
while there are no differences on Ap5A levels (p ¼ 0.245, one way ANOVA). Values
represent means ± SEM (n ¼ 93).
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treatment for the pathology. Peral and co-workers were the ﬁrst to
evaluate the levels of diadenosine polyphosphates in tear secre-
tions in two groups of dry eye symptomatic subjects, one with low
tear secretion volume and another with normal tear volume (Peral
et al., 2006). They found that Ap4A and Ap5Awere increased 5- and
1.5-fold in dry eye subjects with normal tear volume, respectively,
compared with healthy subjects in the same age range. The dinu-
cleotide concentrations were 0.590 ± 0.330 mM for Ap4A and
0.058 ± 0.017 mM for Ap5A. For symptomatic patients with low tear
production the increase was higher, being 100- and 345-fold more
than the value obtained in the healthy group. The concentrations
were 10.68 ± 1.87 mM for Ap4A and 12.45 ± 0.20 mM for Ap5A. From
these results, the authors proposed these molecules as an objective
biomarker for scoring the severity of dry eye.
In 2010, a research paper was published about the diadenosine
polyphosphate concentrations in one of the most severe types of
dry eye, Sj€ogren Syndrome (Carracedo et al., 2010). This autoim-
mune disorder is produced when the immune system attacks its
own exocrine glands by mistake, especially the salivary and
lacrimal ones (Srinivasan and Slomovic, 2007). The mean concen-
trations of Ap4A, and Ap5A in the Sj€ogren syndrome group were
2.54 ± 1.02 mM and 26.13 ± 6.95 mM, respectively. When this group
was divided into two subgroups, normal and low tear secretion, the
concentrations in normal tear secretion group were 0.47 ± 0.20 mM
for Ap4A and 8.30 ± 3.27 mM for Ap5A. The subgroup with low tear
secretion showed dinucleotide concentrations of 4.09 ± 1.36 mM
and 39.51 ± 8.45 mM for Ap4A and Ap5A, respectively. It has been
reported that the upregulated presence of P2Y2 in the salivaryoside polyphosphates on the ocular surface and other eye structures,
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dependent expression of vascular cell adhesionmolecule (VCAM)-1
and provokes the lymphocyte inﬁltration associated with the
inﬂammation (Baker et al., 2008; Schrader et al., 2005). Meanwhile
this receptor has not yet been located in the lacrimal gland, a
similar effect could occur in Sj€ogren Syndrome (Tanioka et al.,
2014). Therefore, the high concentrations of diadenosine poly-
phosphates in Sj€ogren syndrome patients would not be able to
stimulate more lacrimation; they may even increase lymphocyte
inﬁltration.
Another condition related with dinucleoside concentration in
tears is congenital Aniridia. This inherited pathology is a rare dis-
order due to the mutation of the PAX6 gene (Glaser et al., 1992,
1994), located in the short arm of the chromosome 11. The main
feature of aniridia is the partial or total absence of the iris, but the
ocular surface is also affected with limbal stem cell deﬁciency, tear
ﬁlm disorders, corneal keratopathy and dry eye (Mayer et al., 2003).
It seems that dinucleoside play an important role in the progression
of the pathology, since the Ap4A and Ap5A concentration increases
with age, being higher in patients over 40 years of age than in
younger aniridia patients. It has been demonstrated that P2 puri-
nergic receptors are associated with differentiation, proliferation
and neurogenesis in neonatal and adult mouse olfactory epithelium
(Jia and Hegg, 2012). In the corneal epithelium the cell proliferation
process is initiated by P2Y2 receptor activation via the ERK1/2
pathway (Muscella et al., 2004). Therefore, the increased levels of
diadenosine polyphosphates have been proposed as a compensa-
torymechanism to stimulate the proliferation and differentiation of
limbal stem cells that are deﬁcient in aniridia disorder.
Dinucleotide presence in the tear ﬁlm has been related to dry
eye disorders, cell migration and proliferation disorders. Inﬂam-
mation is another biological process where the purinergic receptors
and dinucleotides are involved (Guzman-Aranguez et al., 2014). The
main ocular surface condition, with dry eye, which is probably
associated with inﬂammation is keratoconus. It is a corneal disor-
der characterized by progressive corneal stromal thinning, a cone-
shaped protrusion of the corneal surface (ectasia) (Davidson et al.,
2014; Romero-Jimenez et al., 2010), that creates alterations of the
corneal tissue surface that result in visual distortion and reduced
tear ﬁlm quality. Tissue degradation by keratoconus involves the
expression of inﬂammatory mediators, and therefore patients
exhibit higher levels of pro-inﬂammatory cytokines, cell adhesion
molecules, and matrix metalloproteinases (MMPs) compared withFig. 6. Ap4A concentrations in different ocular conditions. Picture shows the in-
crease on Ap4A levels averages in different pathological processes related with dry eye
condition compared with normal values. Ap4A is a potential biomarker of dry eye
condition, which its cutoff is over 0.5mM Ap4A concentration in tear ﬁlm.
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McMonnies, 2015). The concentration of Ap4A is higher in kerato-
conus patients than in healthy subjects (Carracedo et al., 2015b,
2016). The reasons for this increasing are related with mechanical
stimulation of the corneal epithelial cell, due to eye rubbing or also
gas permeable (GP) contact lenses wearing. In both cases this could
be the trigger to induce the release of the diadenosine
tetraphosphate.
All studies performed on the relationship of Ap4A and dry eye
disorders showed the increment of the concentration of this
molecule in the tear ﬁlm of dry eye patients, so this diadenosine
polyphosphate has been proposed as a diagnostic tool for this
condition. Fig. 6 summarizes the levels of Ap4A concentration in
different ocular conditions compared with normal values.
2.1.5. Presence in contact lens wearers
As commented above, Carracedo and co-workers demonstrated
that forced blinking in healthy subjects provokes an increment of
Ap4A and Ap5A concentration in tears, corroborating In vivo that
these dinucleotides are released by shear stress from the corneal
epithelium (Carracedo et al., 2013). It is reasonable to think that
mechanical stimulation by contact lens wearing may also induce
dinucleotide release, especially if the lens is not well ﬁtted.
There are some different designs and materials for contact
lenses. Both parameters are important to provoke more or less
shear stress over the ocular surface. Broadly speaking, contact
lenses could be manufactured with soft and rigid materials. Actu-
ally, the most common soft material is based on silicone and ﬂuo-
ridemolecules to enhance the oxygen transmissibility, and the rigid
materials are gas permeable, seeking the same oxygen permeability
than soft material (Jones et al., 2013; Nichols et al., 2013). The
design of contact lenses is also an important factor to take into
account. Soft contact lenses have large diameters, beyond the
limbus with a slightly movement during blinking (Maldonado-
Codina and Efron, 2004; Wolffsohn et al., 2013). Nevertheless,
rigid gas permeable lenses have a small diameter with more edge
lift and movement than soft contact lenses, provoking more
discomfort during the wearing (Brennan et al., 1987; Carracedo
et al., 2015a; Cornish and Sulaiman, 1996; Elbendary and Abou
Samra, 2013; Fink et al., 1992). Both contact lenses are bearing
over the cornea Currently, there is a rigid gas permeable special
design, called mini scleral lens and mainly indicated for keratoco-
nus and severe dry eye which does not bear over the cornea,
keeping a post lens tear meniscus between the cornea and the lens.
As with soft contact lenses, its diameter is large, from 15.00 mm to
18.00 mm and therefore saving the cornea and the limbus (van der
Worp et al., 2014).
The effect of contact lens wearing on tear dinucleotide con-
centration has been studied in different material and designs.
Guzman et al. reported the effect of soft contact lenses poorly ﬁtted
in the diadenosine polyphosphates concentration (Guzman-
Aranguez et al., 2007). Twenty-three healthy subjects were
recruited who wore soft contact lenses for 8 h showed Ap4A and
Ap5A tear levels signiﬁcantly increased due to the presence of the
contact lens, being the increasing 20 fold greater for Ap4A than for
Ap5A. They suggested that measurement of tear dinucleotides
might be used as an index of satisfactory contact lens ﬁtting
(Guzman-Aranguez et al., 2015).
Moreover, the relationship between dinucleotides in tears and
rigid gas permeable lenses was studied for two different designs
(Carracedo et al., 2012). Alignment-ﬁt aspheric rigid gas permeable
lenses worn on a daily basis and reverse geometry lenses worn
overnight were ﬁtted in the mentioned study. Both contact lenses
have the same material but not the same indication and wearing
basis. The lenses which are worn during the day provoke moreoside polyphosphates on the ocular surface and other eye structures,
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Fig. 7. Ap4A concentrations in tear from different kinds of contact lenses wearers. A) Picture shows an example of soft contact lens which wearing induces a signiﬁcant increase
in Ap4A concentration (n ¼ 6, *** p < 0.001, t-Student test for related samples), while there is a trend rising Ap5A levels but the difference isn’t signiﬁcant. B) Picture illustrates an
example of scleral lens and the signiﬁcant decrease in Ap4A concentration induced after wearing (8 hours) in patients with keratoconus (n ¼ 26, *p < 0.05, t-Student test for related
samples). C) Graph demonstrates the signiﬁcant trend to increase Ap4A concentration after rigid gas permeable contact lenses in a daily wear (RGP CL), while there are no dif-
ferences in Ap5A concentration except a decrease one week after ﬁtting (n ¼ 22, **p < 0.01, ***p < 0.001, t-Student test for related samples). D) Graph shows a signiﬁcant increase in
Ap4A concentration after 1 day of Corneal Refractive therapy ﬁtting (CRT: reverse geometry gas permeable contact lenses in overnight wear) which then returns to normal values.
There are no differences in Ap5A concentration after CRT wearing except a signiﬁcant decrease one month after ﬁtting (n ¼ 22, **p < 0.01,***p < 0.001, t-Student test for related
samples). Values represent means ± SEM.
G. Carracedo et al. / Progress in Retinal and Eye Research xxx (2016) 1e24 9shear stress on the ocular surface due to the blinking mechanism,
but lenses for overnight wearing do not havemovement due to lack
of blinking during the sleep period. This report found that patients
with Ap4A increased its concentration in tears with both lenses
designs in the ﬁrst day after ﬁtting, increasing 4- and 2-fold
compared with the baseline visit, respectively. After one month,
Ap4A continued increasing signiﬁcantly with alignment-ﬁt lenses
but with lens overnight wear, Ap4A concentrations returned to
baseline levels after 1 week. However, Ap5A concentrations
remained stable during the study in both groups. This result shows
again the effect of the shear stress over the ocular surface stimu-
lating dinucleotide secretion.
As described above, scleral lenses are special contact lenses
indicated for severe dry eye and keratoconus patients which do not
bear over the cornea and its movement in the eye is very limited. It
was interesting to study its wearing over the Ap4A concentration in
tears. A study recently published, shows the results in keratoconus
patients before and after eight hours of wearing (Carracedo et al.,
2016). Ap4A concentrations decreased after scleral lens wear from
0.41 ± 0.71 mM to 0.21 ± 0.52 mM, being statistically signiﬁcant. It
was expected that dinucleotide concentration remained stable but
surprisingly the concentration was lower. This fact could be due to
Ap4A degradation to its metabolites since the tear is stagnant
behind the contact lens during eight hours. Fig. 7 summarizes the
Ap4A concentration for all contact lenses reported in the literature.Please cite this article in press as: Carracedo, G., et al., The role of dinucle
Progress in Retinal and Eye Research (2016), http://dx.doi.org/10.1016/j.p2.1.6. Presence after ocular surface surgery
Another situation where the dinucleotide concentration in the
tear ﬁlm is interesting to be evaluated is after ocular surface sur-
gery. The most common reason to undergo surgery in the ocular
surface is the refractive correction. There are some types of pro-
cedures to do that but the most habitual are Laser in situ kerato-
mileusis (LASIK) and photorefractive keratectomy (PRK). Both
techniques are safe and effective methods producing similar
refractive outcomes (Nejima et al., 2005; Toda, 2008). LASIK, the
lamellar ﬂat cut induces sensory deprivation by severing the
damage of stromal nerves. This nerve ablation provokes some
ocular surface complications as dry eye sensation. However, PRK
causes damage to the corneal sensory nerves by a debridement of
corneal epithelium and stromal ablation (Perez-Santonja et al.,
1999). Presumably, if dinucleotides were released from nerve
endings, patients who have had LASIK or PRK would show changes
in tear levels of diadenosine polyphosphates.
Carracedo and co-workers found that the concentration of Ap4A
rises in tears 5 and 3.5 fold compared with the pre-surgery dinu-
cleotide values in both LASIK and PRK surgery in the next day after
surgery, probably as consequence of corneal damage during the
procedure (Carracedo et al., 2014). After two weeks of both sur-
geries, the concentration decreases close to basal values although in
LASIK it remains statistically higher. At the end of the study, 3
months later, the concentration was very similar to the pre-oside polyphosphates on the ocular surface and other eye structures,
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Ap4A trend to be higher than baseline, but not statistically signiﬁ-
cant, oneweek after LASIK surgery (Guzman-Aranguez et al., 2007).
The results from both studies matched, although it is important to
notice that the lack of statistical signiﬁcance in the study by Guz-
man et al., is probably due to the small size of the sample. For Ap5A,
the concentration remained stable in both studies during all the
period evaluated.
In a non-published study performed by our research group,
dinucleotide concentration in tears was also measured in patients
after Intraocular collamer Lens (ICL) surgery. This refractive surgery
technique consists of introducing an intraocular contact lens in the
anterior chamber through a small incision in the corneal periphery,
close to the limbus (Kamiya et al., 2010; Uusitalo et al., 2002). With
this procedure the corneal neural network is preserved (Alfonso
et al., 2013; Ali et al., 2014). Our preliminary results show that
both Ap4A and Ap5A do not change their concentrations in the tear
ﬁlm throughout the study. This fact suggests that diadenosine
polyphosphates present in tears are not released by the nerve ter-
minals present at the ocular surface, but it rather conﬁrms that the
dinucleotides delivered from ocular surface epithelium is induced
by shear stress.
There are some studies describing how Ap4A has the ability to
stimulate epithelial cell migration. In contrast, Ap5A has the
opposite effect, inhibiting the cell migration (Crooke et al., 2009;
Mediero et al., 2009, 2008, 2006). So, the high concentration of
Ap4A on the day after LASIK and PRK surgery could be used to
accelerate the wound healing process.
2.1.7. Effect on tear secretion
Tear secretion is a physiological process because the tear forms
the interface between the air and the ocular tissues. To lubricate
and to provide nutrients to the ocular surface tissues and to protect
against infections are the more critical features of the tear ﬁlm. For
a correct tear volume and stability, it is very important to maintain
a compensated tear composition. A failure in the tear secretionmay
provoke several negative effects in the ocular surface such as
discomfort, dryness, irritation or corneal and conjunctival staining
(Herrero-Vanrell and Peral, 2007). Dinucleotides participate in the
secretion process of some compounds of tear ﬁlm like aqueous
component, mucins and proteins.
The presence of diadenosine polyphosphates in tears of both
animals and humans suggests that they maymodify the physiology
of the ocular surface. Diadenosine tetraphosphate have demon-
strated their capability to increase the tear volume in the ocular
surface (Pintor et al., 2002b). In the case of Ap4A the increment is up
60% compared to baseline values in experiments performed with
New Zealand white rabbits. Ap5A and Ap6A also signiﬁcantly
increased tear production by about 20% but, Ap2A and Ap3A are
completely ineffective. However, it has not been fully clariﬁed if the
effect of these dinucleotides is to induce tear production at the
lacrymal gland or in other secretory structures. The studies per-
formed with animal models, suppressing the effect with RB-2,
suggest that diadenosine polyphosphates act as agonist of P2Y2
receptors for increasing the tear production (Murakami et al., 2000;
Pintor et al., 2002b). Curiously, the combination of melatonin with
Ap4A enhances the effect of the diadenosine over the tear secretion
in an animal model, but melatonin does not have any effect when it
is applied alone. The authors blocked the effect of this combination
applying luzindole, an antagonist of melatonin receptors (Hoyle
et al., 2006). It has not been described how melatonin and its re-
ceptors increase the effect of Ap4A but a possible mechanism is the
heterodimerization of both dinucleotides and melatonin receptors.
Both families receptor are coupled to G-protein and it has been
suggested that actually these receptors could be organized asPlease cite this article in press as: Carracedo, G., et al., The role of dinucle
Progress in Retinal and Eye Research (2016), http://dx.doi.org/10.1016/j.pheterodimers between different G-protein coupled families
(Levoye et al., 2006).
Other dinucleotides which demonstrate their secretagogue
propierties is Gp4G and Up4U. Recently in our lab, it has been
proved that diguanine tetraphosphate (Gp4G) increases tear
secretion in around 40% above normal tear values in New Zealand
White rabbits. As diadenosine tetraphosphate, it is expected that
this action is mediated by P2Y2 (Guzman-Aranguez et al., 2015). But
the dinucleotide probably most studied is Up4U, also called INS-
365. First studies in animal models showed its properties to
enhance tear secretion (Fujihara et al., 2001; Murakami et al., 2000,
2002; Yerxa et al., 2002a). These results, as a secretagogue, were the
prelude of Diquafosol, an ophthalmic formulation based on this
compound, developed as a new treatment for dry eye and was
recently approved for marketing in Japan and South Korea
(Jacobson et al., 2012; Nakamura et al., 2012).
Diquafosol has shown its capability to increase the aqueous and
mucin portion of tears (Murakami et al., 2004; Nakamura et al.,
2012; Takamura et al., 2012; Tauber et al., 2004). In recent years,
diquafosol has been used for treating different conditions related
with dry eye (Table 2). This dinucleotide improves the tear secre-
tion and symptomatology in Sj€ogren syndrome (Bremond-Gignac
et al., 2014; Yokoi et al., 2015), aqueous deﬁcient dry eye (Koh
et al., 2013a, 2014), contact lens wearers (Nagahara et al., 2015),
Meibomian gland dysfunction (Arita et al., 2013; Yamaguchi et al.,
2015), dry eye related with cataract surgery (Miyake et al., 2014;
Park et al., 2015), even in normal eyes (Gendaszewska-Darmach
and Kucharska, 2011; Nam et al., 2015; Yokoi et al., 2014).
Regarding the safe use of diquafosol, the majority of adverse re-
actions, found in different clinical trials, were of mild severity, and
no serious treatment-related adverse events were reported.
Adverse reactions were observed in 6.3% of patients, and the major
adverse reactions were eye irritation, and eye pain. It seems that
good tolerance shown by diquafosol ophthalmic solution 3%
remained in the longer term (Takamura et al., 2012;Wu et al., 2015;
Yamaguchi et al., 2014).
2.1.8. Effect on tear components
The tear ﬁlm is a complex solution composed of proteins, lipids,
carbohydrates and electrolytes. Two main features of the tear ﬁlm
are to protect the ocular surface against potential pathogens and to
lubricate and wet the corneal and conjunctival epithelia. So, the
tear ﬁlm has some antimicrobial components that are able to kill
the pathogens or at least to inhibit their replication. The main
proteins in the tear ﬁlm performing this task are lysozyme, lacto-
ferrin, immunoglobulin A (IgA) and tear lipocaline (Farris, 1986;
Kuizenga et al., 1996; Cabrera et al., 1997).
Lysozime presents a bactericide action against gram-positive
bacteria, such as Micrococus lisodeikticus, catalyzing the hydrolysis
of 1,4-b junctions between N-acetylmuramic acid and N-acetyl-D-
glucosamine in the main chain of peptidoglycans of cell membrane
(Burman et al., 1991; Qasba and Kumar, 1997). This protein is
secreted by the main and accessories lacrymal glands, representing
25% of total proteins in the tear ﬁlm. Peral and co-workers inves-
tigated the effect of dinucleotide instillation on the lysozyme
concentration in the tear ﬁlm (Peral et al., 2008). Their hypothesis
was based on several studies that have shown a decrease in the
concentration of lysozyme in patients with dry eye (Caffery et al.,
2008; Mackie and Seal, 1984; van Bijsterveld, 1969). The topical
application of 100 mM of Ap4A and Up4U (aka diquafosol) increased
the lysozyme levels after one hour of instillation, remaining higher
than baseline during four hours. The maximum value was reached
at two hours for both dinucleotides, being the increase in lysozyme
concentration of 93% for Ap4A, 119% for Up4U.
Another interesting molecule with bacteriostatic properties isoside polyphosphates on the ocular surface and other eye structures,
reteyeres.2016.07.001
Table 2
Summary of studies about Diquafosol application in the eye and their effects on different kinds of patients.
Molecules Parameters Patients Posology Effect Reference
3% Diquafosol vs. 0.1%
sodium hyaluronate
Tear stability;
corneal integrity
Dry eye after cataract surgery 6 times a day after
cataract surgery
The Diquafosol group
showed signiﬁcantly
superior TBUT
(P < 0.001), corneal
ﬂuorescein (P ¼ 0.045),
and conjunctival
staining (P ¼ 0.001)
(Park et al., 2015)
3% Diquafosol Dry eye symptoms;
tear stability;
corneal integrity
Dry eye (DE) patients wearing
contact lenses (CLs) or with
concomitant meibomian gland
dysfunction (MGD) or
conjunctivochalasis
Not described Signiﬁcant
improvement in total
symptom score, corneal
and conjunctival
ﬂuorescein staining
score, and tear ﬁlm
break-up time
(Yamaguchi et al., 2015)
3% Diquafosol vs. 0.1%
sodium hyaluronate vs.
Saline solution
tear stability;
corneal integrity
Normal eyes Not described 3% Diquafosol
signiﬁcantly increased
TBUT for up to 15 min
after application
(Nam et al., 2015)
3% Diquafosol Tear volume; Tear
stability
Sj€ogren Syndrome 6 times a day The tear meniscus
radius and the tear ﬁlm
breakup time were
signiﬁcantly improved
(Yokoi et al., 2015)
3% Diquafosol Tear Volume Contact lens wearers Not described Tear Meniscus Heigth
signiﬁcantly increased
(P < 0.05) at 5 min,
15 min, 30 min, and
60 min compared with
the baseline values.
(Nagahara et al., 2015)
3% Diquafosol Corneal surface
wetting
Cataract surgery 6 times daily for 4
weeks before surgery
Diquafosol 3.0%
ophthalmic solution in
patients with senile
cataract was effective in
enhancing the
intraoperative corneal
surface wetting
property improving
optical clarity during
surgery.
(Miyake et al., 2014)
3% diquafosol Dry eye symptoms;
Visual quality;
corneal staining
Dry eye after laser in situ
keratomileusis (LASIK)
6 times daily Better staining and
symptomatology scores
(Mori et al., 2014)
3% Diquafosol Dry eye symptoms;
tear stability
Aqueous-deﬁcient dry eye Not described Diquafosol ophthalmic
solution signiﬁcantly
improved dry eye
symptoms, corneal
staining and BUT.
(Koh et al., 2014)
0.3% sodium hyaluronate
vs. 3% Diquafosol vs. 2%
rebamipide
Optical quality
(high order
aberration and light
scattering)
Normal eyes Not described A signiﬁcant increasing
of High order
aberrration was found
for hyaluronate and
light scattering for
rebamipide compared
with Diquafosol
(Koh et al., 2013b)
3% Diquafosol Lid margin
abnormalities; tear
volume; corneal
integrity
Meibomian gland dysfunction 4 times a day Ocular symptoms, lid
margin abnormalities,
SPK score and meibum
grade were decreased.
Break-up time and tear
ﬁlm meniscus were
increased
(Arita et al., 2013)
1% Diquafosol vs. 3%
Diquafosol
Dry eye symptoms;
tear stability;
corneal integrity
Dry eye symdrome 6 time a day Both concentrations
improved corneal
integrity and
symptomatology
(Matsumoto et al., 2012)
0.1% sodium
hyaluronate þ 3%
Diquafosol
Dry eye symptoms;
tear volumne; tear
stability; cornreal
integrity
Dry eye symdrome Not described When sodium
hyaluronate
monotherapy was
insufﬁcient, Diquafosol
tetrasodium was
effective in improving
objective and
subjective symptoms
(Kamiya et al., 2012)
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Fig. 9. Variations in mucin cloud height after dinucleotides and nucleotides (ag-
onists P2Y2) treatment. Graph shows the signiﬁcant increase on mucin cloud height
in rabbits after the treatment with all nucleotides (n ¼ 3, Tukey-Kramer test; *p < 0.05,
**p < 0.01, ***p < 0.001), which is maximal after INS-365 application being about 3-fold
higher than control. Values represent means ± SD.
G. Carracedo et al. / Progress in Retinal and Eye Research xxx (2016) 1e2412lactoferrin. Particularly, lactoferrin is an iron-binding protein, thus
reducing the availability of iron necessary for microbial growth and
survival. Additionally, the anti-inﬂammatory actions of this protein
have also been proposed (Arnold et al., 1977; Conneely, 2001). The
dinucleotide Ap4A was able to increase lactoferrin concentration
from 68 ± 4 mg/ml to 83.17 ± 9.89 mg/ml at 1 h of instillation. This
effect was slightly increased at 2 h and continued for 2 h more until
it returned to the baseline values (Loma et al., 2016).
The increasing of lysozyme and lactoferrin after dinucleotides
instillation is mediated by purinergic receptors activation. The
presence of different P2X and P2Y receptors on the ocular surface
were noted. Ap4A and Up4U mainly stimulate P2Y2, but Ap4A can
also act on P2X2, P2X4, P2Y1 and P2Y2 receptors. Previous studies
showed that the tear secretion is stimulated with Ap4A by P2Y2
receptors (Fonseca et al., 2015; Pintor et al., 2002a). The antagonists
used in the study of lysozyme and the lack of effect of some nu-
cleotides such as UDP and ADP (preferential agonists of P2Y6 and
P2Y1 but also agonists of P2Y12, P2Y13 and P2Y14) (Ralevic and
Burnstock, 1998) may suggest that P2Y2 is responsible for this,
since only P2Y2 actions have been demonstrated on lysozyme
production (Peral et al., 2008).
For lactoferrin, Ap4A action was also mediated by purinergic
receptors activation. Although the lacrymal gland is the major
source of tear lactoferrin, it has been demonstrated that ocular
surface epithelial cells also produce detectable amounts of lacto-
ferrin (Flanagan and Willcox, 2009; Santagati et al., 2005) with
higher expression in conjunctival than corneal epithelial tissue
suggesting that activation of P2 receptors identiﬁed in these lo-
calizations could also be involved in lactoferrin secretion. The au-
thors used some selective antagonist for P2Y1, P2X4 and P2Y2, and
they found that only AR-C118925XX (selective P2Y2 purinergic re-
ceptor antagonist) blocked the effect of Ap4A. Moreover, PPADS
(antagonist of mainly P2X but also P2Y1 receptors) was also tested
to evaluate the activation of other P2X receptors, and indeed it was
able to partially reverse Ap4A action. Altogether, it seems that the
lactoferrin production is mainly triggered by P2Y2 purinergic re-
ceptor, but the participation of a P2X and a P2Y1 receptor cannot be
discarded.
Since both proteins, lysozyme and lactoferrin are the ﬁrst de-
fense mechanism against microbial infection, dinucleotides might
provide additional protection by increasing the natural agents in
tears of healthy subjects. Moreover, the increasing of these proteins
could help to stabilize the tear ﬁlm, avoiding an excessive tear
evaporation rate and ocular surface desiccation. In particular, the
lactoferrin diminishes the superﬁcial tension of the tear ﬁlm (MillarFig. 8. Visualization of the mucin secretion by confocal microscopy. Impression cytology
Shiff, were dehydrated in different levels of ethanol, put on xylol and ﬁnally mounted in co
view of goblet cells and their mucin secretion (red) and conjunctival epithelial cells (green). B
Perpendicular view of mucin cloud after INS-365 treatment.
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Other important molecules for tear ﬁlm stability and homeo-
stasis are the mucins. Mucins are high molecular weight glyco-
proteins that are produced by corneal and conjunctival epithelial
cells present in the ocular surface (Murube, 2012). There are three
families of ocular mucins based on their amino acid sequence:
transmembrane (MUC1, MUC3A, MUC3B, MUC4, MUC12, MUC13,
MUC15, MUC16, MUC17, MUC20, and MUC21), secreted gel-
forming (MUC2, MUC5AC, MUC5B, MUC6, and MUC19) and
secreted soluble mucins (MUC7 and MUC9). Other mucins such as
MUC8 andMUC11 have not been classiﬁed yet (Corrales et al., 2011;
Murube, 2012).
The main actions of mucins are to clean, lubricate and protect
the ocular surface from adverse environmental conditions
(Mantelli and Argueso, 2008; Murube, 2012).
Based on the response elicited by UTP and ATP on isolated hu-
man and rabbit conjunctivas, Jumblatt and Jumblatt suggested the
involvement of P2Y2 purinergic receptors in mucin secretion
(Jumblatt and Jumblatt, 1998). Moreover, Murakami et al. showed
that the UTP/ATP- mediated mucin secretagogue effect was
reversed in rabbits pre-treated with suramin (Murakami et al.,
2003). The antagonist suramin blocks all P2Y receptors with the
exception of the P2Y4 receptor (von Kugelgen, 2006). Thus, and
taking into account that P2Y2 receptor is expressed in thesamples were preserved in 96% ethanol and after being processed by the periodic acid
verslips for further observations by means of the laser confocal microscope. A) Frontal
) Perpendicular perspective of mucin cloud secreted by goblet cell in basal condition. C)
oside polyphosphates on the ocular surface and other eye structures,
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2003), it has been considered that the P2Y2 receptor governs the
conjunctival mucin secretion. Both Ap4A and Up4U are agonists of
P2Y2 receptor so they should promote the mucin secretion from
conjunctival Goblet cells.
The ﬁrst study on dinucleotides and mucin secretion in tears
was published in 2001 (Fujihara et al., 2001). They found that INS-
365, aka Up4U and also termed diquafosol (see section 2.1.7), has
the ability to evoke mucin secretion on In vivo conjunctivas of a rat
dry eye model. In 2004 they corroborated their results in the New
Zealand white rabbit model (Pintor et al., 2004a). They concluded
that INS365 restored moisture and hydration of the ocular surface
of rats by its effects on tear andmucin secretion. Other authors have
found the same effect of INS-365 in different animal models,
increasing Goblet cell Density andmucin production (Fujihara et al.,
2002; Kojima et al., 2014; Terakado et al., 2014).
Our research group performed a study to evaluate the possible
involvement of other P2Y receptors, not only P2Y2, such as P2Y4 and
P2Y6 in rabbit conjunctival mucin secretion, testing the mucin
secretagogue effect of the dinucleotide Ap4A and INS-365. The
technique used for ocular mucin visualization was confocal laser
scanningmicroscopy (Fig. 8). This technique, following the protocol
stablished by Peral and Pintor, allows us to measure mucin cloud
height (MCH) over the goblet cell. In this sense, all the dinucleotides
tested evoked a signiﬁcant increase of the MCH parameter in
comparisonwith control animals. The rank order of effect on mucin
secretion was INS-365 (MCH ¼ 9.50 ± 1.72 mm) greater than UTP
(MCH ¼ 6.50 ± 0.49 mm) and greater than Ap4A
(MCH ¼ 3.75 ± 0.79 mm), Fig. 9.
It was also observed that the secretory effect of INS-365 and UTP
was more robust than that obtained by Ap4A. This fact suggests the
involvement not only of P2Y2 receptors but also of other uracil
nucleotide-sensitive receptors. To determine the possible purino-
ceptors involved in mucin secretion RB-2, suramin and PPADS an-
tagonists were applied on rabbit conjunctiva in the presence or
absence of INS-365. RB-2 was the most effective purinoceptor
antagonist, reducing INS365-evoked MCH by 3.5-fold (MCH RB-
2 þ INS365 ¼ 3.18 ± 0.83 mm versus MCH INS-
365 ¼ 11.20 ± 0.37 mm). Suramin and PPADS also reduced the MCH
value in comparison with rabbits treated with INS365 alone, but
they were less effective. Taking into account that RB-2 is a very
weak antagonist of P2Y2 receptors, a modest antagonist of P2Y4
receptors and a potent antagonist of P2Y6 receptors (Abbracchio
and Ceruti, 2006; von Kugelgen, 2006), it seems that P2Y6, and to
a lesser extent P2Y4 receptors, play an important role in rabbit
conjunctival mucin secretion.
There is only one study regarding INS-365 (Diquafosol) and
mucin production in human conjunctiva epithelium. Sigheyasu
et al. related a signiﬁcant increase of sialic acid concentration, a
good marker for evaluating mucins in biological samples
(Shigeyasu et al., 2015a, 2015b), in tears after Diquafosol instillation
in healthy human eyes. This ﬁnding corroborates the data described
in animal model by other authors (Fujihara et al., 2002; Kojima
et al., 2014; Terakado et al., 2014).
2.1.9. Contact lens delivery of dinucleoside polyphosphates
The most common system to treat ocular conditions is by
applying eye drops (Kojima et al., 2008; McCann et al., 2012).
Sometimes, the use of punctal plugs are necessary to increase the
resident time of the active molecule on the ocular surface
(Karcioglu and Fleming, 2008). Probably the major challenge to
treating ocular pathologies, including surface disease such as dry
eye, is to enhance the bioavailability, reduced by the complex
structure of the ocular surface. In this context, contact lenses have
been proposed as new vehicle for drug delivery. Contact lenses arePlease cite this article in press as: Carracedo, G., et al., The role of dinucle
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ﬁlm. The clearance time of the post-lens tear ﬁlm in soft contact
lenses is about 30 min (McNamara et al., 1999). Thus, ophthalmic
drugs released from the contact lenses will have a residence time in
front of the cornea for at least 30 min compared to 2 min for eye
drops. This method is currently being investigated to deliver mol-
ecules as anti-inﬂammatory, antibiotics or lubricants molecules on
the ocular surface. In the case of dinucleotides, contact lens delivery
system has been used with Ap4A to improve the secretagogue
function of this molecule.
For experiments, two materials of hydrophilic contact lenses
(Omaﬁlcon A and Ocuﬁlcon A) and another two materials of
hydrogel-silicone contact lenses (Comﬁlcon A and Balaﬁlcon A)
were used. All lenses were uploaded with 1 mM Ap4A solution.
In vitro experiments showed that dinucleotide delivery from con-
tact lens was more prolonged with non-ionic material (Omaﬁcon A
and Comﬁlcon A) than ionic material Ocuﬁlcon A and Balaﬁlcon A).
Moreover, the delivery rate was better in hydrogel-silicone lenses
than hydrophilic lenses. In vivo experiments reported that Ap4A
delivery from non-ionic hydrogel-silicone contact lens was able to
induce tear secretion higher than baseline values during 360 min
(Dominguez-Godinez et al., 2013). It seems that the ionic charge of
the contact lens materials could be the major factor in Ap4A de-
livery. In this sense, it is important to note that Ap4A is a dinucle-
otide presenting four phosphates that in neutral pH present four
negative charges (Patane et al., 2011). This could be the reason why
those lenses with ionic charge, which is also negative, may repel
Ap4A and the molecule delivery is faster.
2.1.10. Effect on corneal wound healing
The corneal epithelium are in permanent renovation, being
complete every 7e10 days (Liu and Kao, 2015). The proliferation
and differentiation of limbal cells are responsible for the epithelium
renovation. The new epithelial cells come to the mitotic activity of
limbal basal cells which replace the old epithelial cells following a
centripetal and superﬁcial movement (Lemp and Mathers, 1989).
When the epithelium is damaged, the reepithelization process or
wound healing begins, following three phases: latency phase,
migration phase and cell mitosis (Suzuki et al., 2003).
There is cell reorganization during the latency phase. The syn-
thesis cytoskeletal proteins, such as actine, vinculin and taline, and
ocular surface glycoproteins begins in this phase to act in the
migration phase. Moreover, the wound area increases in this phase
due to the action of some leucocytes from the tear ﬁlm, eliminating
necrotic cells (Panjwani et al., 1990; Suzuki et al., 2003). The
migration phase mainly depends on actin ﬁlaments activation and
other proteins to promote the movement of the cells from the pe-
riphery to the wound centre (Kurpakus et al., 1999). Finally, the cell
division phase completes the wound healing process (Lehrer et al.,
1998).
It has been described that some molecules released from the
corneal nerves stimulate the wound healing process after ocular
surface injuries (Muller et al., 2003). Among natural substances,
nucleotides and dinucleotides present in tears have been shown to
be very active to modify the rate of healing (Bowman and Green,
1981; Pintor et al., 2004a). Experiments performed in our labora-
tory on an animal model, demonstrated that the levels of Ap4A and
Ap5A are signiﬁcantly reduced after the damage, recovering after
10 h. The same ratio of Ap4A/Ap5A concentration in tears remained
stable. This means that diadenosine polyphosphates remain low
during the latency phase and recover during the migration phase,
suggesting their involvement in the migration process (Mediero
et al., 2006).
Nucleotides inﬂuence the corneal epithelial cells healing rate by
either accelerating or decelerating the healing process. Pintor et al.oside polyphosphates on the ocular surface and other eye structures,
reteyeres.2016.07.001
G. Carracedo et al. / Progress in Retinal and Eye Research xxx (2016) 1e2414found that the estimated healing time was for saline, Ap3A, Ap4A
and Ap5Awere 32.2 ± 2.0 h, 35 ± 2.6 h, 26.0 ± 0.6 h and 29.2 ± 2.2 h,
respectively. It means that only diadenosine tetraphosphate pro-
vokes an increase in the wound healing rate (Pintor et al., 2004a).
Based on these results, Mediero et al. evaluated the role of dia-
denosine polyphosphate in the epithelial cell migration, performed
in primary corneal epithelial cell culture (Mediero et al., 2006).
Ap4A accelerate 5 h the wound healing whereas Ap3A and Ap5A
delayed it 6.5 h and 10 h respectively. The opposite effects may be
justiﬁed by the activation of different P2Y receptors subtypes pre-
sent in the ocular surface (Klepeis et al., 2004;Weinger et al., 2005).
Both Ap3A and Ap5A are agonist of P2Y6 and Ap4A of P2Y2. So, it
seems that P2Y2 receptor stimulates the wound healing process
and P2Y6 inhibits it.
Due to there not being a selective agonist for P2Y2 receptor, its
implication in epithelial wound healing has been studied by
silencing it with small interference RNA (siRNA) against the rabbit
P2Y2 receptor. The authors performed In vitro and In vivomigration
analysis showed that the silencing process reduced the corneal cells
migration when Ap4A was instilled, even showing less wound
healing than control group (without Ap4A instillation). It seems to
demonstrate the effect on wound healing of the natural Ap4A in
tears, mediated by P2Y2 (Crooke et al., 2009). Moreover the
involvement of the P2Y2 receptor has been demonstrated by other
authors (Boucher et al., 2010; Sanderson et al., 2014). Mediero et al.
demonstrated that the activation of the P2Y2 receptor with Ap4A,
accelerates corneal epithelial cell migration during wound healing
with the activation of mitogen-activated protein kinase (MAPK)
and cytoskeleton pathways, whereas activation of the Ap3A/P2Y6
receptor signals only the MAPK pathway (Mediero et al., 2008).
Moreover, phospholipase C/Protein Kinase C (PLC/PKC) pathway in
the activation of ERK1/2 and ROCK-I is involved (Mediero et al.,
2011).
2.1.11. Effect on epithelial permeability
Corneal permeability has also been studied under the di-
nucleotides application. Eye diseases are often treated by topically
administered drugs. However, as commented in section 2.1.9,
ocular drug delivery is strongly limited by the barriers of the eye
resulting in poor drug bioavailability (Kompella et al., 2010). The
cornea is a chemical and mechanical barrier that stops the entry of
any foreign body, included drugs, to the anterior chamber (Leong
and Tong, 2015). The corneal epithelium is the layer with a stron-
ger barrier function (Gobbels et al., 1990; McNamara et al., 1997;
Yokoi and Kinoshita, 1995), meanwhile the stroma and endothe-
lium give less resistance to transcorneal permeability (Huang et al.,
1983, 1989).
Fujihara et al. evaluated the corneal barrier function with a
modiﬁed anterior ﬂuorometer measuring ﬂuorescein penetrance
(Fujihara et al., 2001). They found that INS-365 as low as 1% de-
creases the dye penetrance approximately by 50%. They suggested
that this action was mediated by P2Y2 but they did not test the
implication of this metabotropic receptor.
The involvement and the effect on corneal permeability medi-
ated by P2Y2 receptors have been quite different when studied by
other authors. By means of the transepithelial electrical resistance
(TEER) it has been possible to demonstrate that the dinucleotide
Ap4A is able to open the paracellular corneal epithelial barrier being
the effect transitory and maximal 2 h after the application of the
dinucleotide (Loma et al., 2015b). This is an interesting function of
Ap4A because its topical application could “open the door” to other
compounds to treat internal ocular pathologies such as glaucoma or
intraocular infections.
The possibility of facilitating the paracellular way for the de-
livery of compounds within the eye presents two main advantages:Please cite this article in press as: Carracedo, G., et al., The role of dinucle
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concomitantly and second less adverse events In this way, Ap4A
administration showed that, when it was topically applied two
hours before the application of a classical adrenergic compounds
for glaucoma treatment, the concentrations of brimonidine and
timolol in the aqueous humour increased from 64.3 ± 5.3 nM to
240.6 ± 8.6 nM and from 58.9 ± 9.2 nM to 183.7 ± 6.8 nM respec-
tively, and this also produced a more robust reduction in IOP than
when they are applied alone (Loma et al., 2015a).
Diadenosine tetraphosphate effect is produced by the tempo-
rary disruption of the tight junctions present in the corneal
epithelium (Loma et al., 2015b). These tight-junctions form an
epithelial junctional complex with the adherens junctions and
desmosomes to avoid the entry of substances within the eye (Ban
et al., 2003). Tight junctions are multifunctional and dynamic
protein complexes that connect adjacent cells by sealing the
intercellular space between cells preventing the paracellular
movement of solutes, ions and water. The main proteins forming a
tight junction in the cornea are occludin (Langbein et al., 2002),
claudins (Ban et al., 2003) and zonula occludens-1 (ZO-1) (Ban
et al., 2003; Sosnova-Netukova et al., 2007; Yoshida et al., 2009).
It was possible to measure the effect of Ap4A on tight junction
proteins bywestern blot and the threementioned proteins, claudin,
occludin-7 and ZO-1, showed a clear reduction in its expression 2 h
after the dinucleotide application, the fall of expression being 59.3%
for ZO-1, 57.9% for occludin-7 and 58.8% for claudin (Loma et al.,
2015b).
The implication of P2Y2 in Ap4A in thementioned effect was also
demonstrated. An elegant approach to demonstrate the importance
of this receptor on the Ap4A effect on corneal barrier was per-
formed by using P2Y2 receptor siRNAs. Silencing the P2Y2 receptor
completely abolished the effect of drug delivery carried out by
Ap4A. Moreover, the proteins that form the commented tight-
juntions remained unaltered in the presence of the dinucleotide.
As happens in the Ap4A wound healing stimulation, the effect of
Ap4A was mediated by P2Y2 activation coupled with ERK1/2
pathway (Loma et al., 2015b).
2.2. Dinucleoside polyphosphates in the anterior pole
2.2.1. Presence in the aqueous humour
Aqueous humour, the secretion that nourishes the avascular
structures of the eye such as cornea and lens, contains dinucleoside
polyphosphates at low micromolar concentration (Castany et al.,
2011; Pintor et al., 2003). Among the different dinucleotides, Pin-
tor and colleagues have identiﬁed and quantiﬁed the presence of
Ap4A (0.34 mM) and Ap5A (0.08 mM) in the aqueous humour of
rabbits (Pintor et al., 2003). These compounds are also present in
the aqueous humour of human, with levels of 0.020 mM (for Ap4A)
and 0.021 mM (for Ap5A) (Castany et al., 2011). Moreover, in glau-
coma patients, Ap4A concentration is 15 times higher than in
normal individuals (Castany et al., 2011).
The origin of the dinucleotides in aqueous humour has only
recently been elucidated as a mechanism dependent of the ciliary
body epithelium although some clues about their extracellular
origin were suggested some years ago (Pintor et al., 2003). In the
case of nucleotides such as ATP, Mitchell and colleagues have
demonstrated its direct release from ciliary epithelial cells in cul-
ture (Mitchell et al., 1998).
A key point in the release of nucleotides to the aqueous humour
is the TRPV4 channel described as ciliary body epithelial cells which
indeed mediates in the release of different substances to the
aqueous humour (Alkozi and Pintor, 2015). In this sense, either by
producing osmotic changes, which is one of the main features of
this TRPV channel, or by using selective agonists such asoside polyphosphates on the ocular surface and other eye structures,
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tetraphosphate almost triplicates its extracellular concentration
(Pintor et al., 2011). The mechanism of such release is mostly car-
ried out by pannexins (pannexin 1) in a percentage of 40%, the same
percentage with connexins and ﬁnally 20% by exocytosis (Pintor
et al., 2011). The molecular mechanisms that connect TRPV4 with
pannexin and connexons are still under investigation, since the
exocytosis may be explained by the typical Ca2þ entry produced
when the TRPV4 channel is activated.
In general, the activation of a TRPV4 channel is relevant since
changes in the hydrostatic and osmotic pressure, typical in many
types of glaucoma, may respond to such variations in the aqueous
humour dinucleotide concentration. Nevertheless, it is important to
note that another important structure which may contribute to the
release of nucleotides and dinucleotides to the aqueous humour, is
the lens. Several studies have reported that in this structure the
release of nucleotides such as ATP is also performed by means of a
TRPV4 and via mechanisms that involve the participation of hem-
ichannels (Shahidullah et al., 2012a, 2012b).
The presence of the compounds Ap3A (Szwergold and Lal, 2005)
and Ap4A as well as the release of the latter, has been demonstrated
inmice. Interestingly, the release of thementioned substance varies
depending on the mice strain used. The strains FVB and C57, release
equivalent amounts of Ap4A providing concentrations of about
1.3 nM, while in the glaucomatous mice, DBA/2J, the concentration
of Ap4A is 5.9 nM. Indeed, the changes in the aqueous humour,
making it more hypoosmotic, despite affecting the three mice
strains, was particularly remarkable in the DBA/2J glaucomatous
animal when the levels increased to 61 nM. It seems, therefore, that
the lens presents a very relevant role in the release of nucleotides to
the aqueous humour and particularly in models of glaucoma as
indicated. The ability of the lens to release nucleotides is probably
due to its enormous concentrations of nucleotides, being the tissue
with higher nucleotide levels in the whole body (Pintor, 2011). It is
interesting to notice that nucleotides, apart from developing the
tasks of keeping the pumps and transporters, operative, nucleo-
tides and dinucleotides develop a physical action avoiding the entry
of some UV wavelengths to the retina by absorbing this damaging
light (Pintor, 2011).
The concentration, and thereby function, of Ap4A and Ap5A in
the aqueous humour can also be controlled by ecto-nucleotidases.
Corneal endothelial cells express NTPDase1 isoform as well as eN
enzymes (Gomes et al., 2005). Additionally, non-pigmented ciliary
epithelial cells and ciliary stromal cells (endothelial and interstitial
cells) express ENPP1, NTPD1 and eN/5NTE (Braun, 2010;
Farahbakhsh, 2003). On the other hand, trabecular meshwork
cells express ENPP1-3, NTPD2 as well as NTPD8 and 5NTE (Li et al.,
2011). Since all these structures bathed by aqueous humour also
present purinergic receptors, dinucleotides and their metabolites
(i.e. ATP, ADP and adenosine) can regulate their physiological
functions including corneal endothelial ﬂuid transport, aqueous
ﬂuid production and drainage (Crooke et al., 2008).
2.2.2. Effect on intraocular pressure
2.2.2.1. General effects. The intraocular pressure (IOP), which
maintains the spherical shape of the eye, depends on the balance
between the aqueous humour production and its drainage (Goel
et al., 2010). Aqueous humour is secreted by the ciliary processes
of the ciliary body and is drained, mainly, through the trabecular
meshwork into the canal of Schlemm (Goel et al., 2010). Since both
structures express nucleotide receptors (Crooke et al., 2008;
Guzman-Aranguez et al., 2013), dinucleotides but also their me-
tabolites could regulate aqueous humour secretion/drainage and
thereby modify IOP. Some dinucleotides such as the diinosine
polyphosphates can also regulate IOP. Guzman-Aranguez andPlease cite this article in press as: Carracedo, G., et al., The role of dinucle
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(Ip5I) to increase IOP in normotensive rabbits (Guzman-Aranguez
et al., 2012). Conversely, diinosine triphosphate (Ip3I) and diino-
sine tetraphosphate (Ip4I) reduce IOP, the latter being the more
potent hypotensive compound (Guzman-Aranguez et al., 2012).
Indeed, the topical application of Ap4A in normotensive rabbits
reduces IOP in a concentration dependent manner (Pintor et al.,
2003). Conversely, Ap5A (also present in aqueous humour), Ap2A
and Ap3A increase the IOP of these animals (Pintor et al., 2003).
Although the topical application of diadenosine tetraphosphate on
animal models is the reduction of IOP, studying the effects on the
main ocular structures responsible for the aqueous humour dy-
namics, trabecular meshwork and ciliary body, the effects are the
opposite. While in the trabecular meshwork Ap4A produces facili-
tation in the aqueous humour drainage, in the ciliary body this
dinucleotide produces an increase in aqueous humour production.
2.2.2.2. Effect on the trabecular meshwork. Trabecular meshwork
presents many P2Y receptors, mainly P2Y1, P2Y2, and P2Y4 in
bovine TM cells (Soto et al., 2005) and P2Y11 in a cellular line of
human trabecular meshwork (Crosson et al., 2004). Diadenosine
polyphosphates do not activate all these receptors in the same way.
For instance, Ap3A and Ap4A can mainly activate P2Y1 (Schachter
et al., 1996) receptors, nevertheless it is important to note that
Ap4A is also able to trigger P2Y2 and P2Y4 receptors (Lazarowski
et al., 1995). Indeed, the application of Ap3A and Ap4A increased
outﬂow facility at low micromolar concentrations (Soto et al.,
2005), thereby contributing to the reduction in IOP previously
detected in other animal models (Pintor, 2005). The application of
diadenosine polyphosphates in trabecular meshwork cells pro-
duces an increment in the intracellular Ca2þ, but only in pharma-
cological studies, carried out by means of different mono and
dinucleotide concentrations, as well as the use antagonists,
permitted to identify which is responsible for the facilitation of
outﬂow and Ca2þ mobilization. In this sense, the P2Y1 receptor
agonist 2-MeS-ATP, together with Ap3A and Ap4A, suggests that
this is the main P2Y receptor involved in the mentioned effects.
Moreover, the blockade obtained by the P2Y1 selective antagonist
MRS-2179 on the drainage facilitation induced by Ap4A, and the
sharp inhibition in the Ca2þ increases, as previously commented,
conﬁrms that this is themain receptor responsible for the reduction
of IOP at the trabecular meshwork (Pintor, 2005).
2.2.2.3. Effects on the ciliary body. Some of the ﬁrst actions where
the effects of nucleotides and dinucleotides were detected in the
ciliary body demonstrated the presence of P2X2 receptors in the
ciliary muscle (Peral et al., 2009). In this location and by means of
the same ionotropic receptor, diadenosine tetraphosphate exerts
the same actions other mononucleotides do. Interestingly, the ac-
tion of Ap4A, seems to occur on the cholinergic terminals inner-
vating the ciliary muscle. These terminals after the activation of the
dinucleotide promote the release of acetylcholine that contracts the
muscle via muscarinic receptors. This contraction pulls the scleral
spur opening the irido-corneal angle and therefore facilitating the
evacuation of the aqueous humour by the trabecular meshwork
(Pintor, 2005).
In a clear difference to what was described previously, other
actions of diadenosine polyphosphates, mainly Ap4A are mediated
by P2Y2 receptors present in the ciliary epithelium (Martin-Gil
et al., 2012). The presence of this receptor and its activation pro-
duces an effect which is opposite to the one observed in the ciliary
muscle and in the trabeculum. In the ciliary body the activation of
this receptor with dinucleotides or mononucleotides (selective for
the P2Y2 receptor) produces a rise in IOP. This effect can be
demonstrated when the P2Y2 receptor is silenced by means of aoside polyphosphates on the ocular surface and other eye structures,
reteyeres.2016.07.001
Fig. 10. Schematic representation of the involvement of the purinergic signaling in intraocular hypertension. Extracellular Ap4A activates the PLC/PKC signaling pathway
through the stimulation of P2Y2 purinergic receptors in non-pigmented ciliary epithelial cells. The activation of protein kinase C (PKC) causes trafﬁcking of Aquoporin 1 (AQP1) to
plasma membrane mediated by the phosphorylation of at least three subunits of AQP1. In the same way, the activation of phospholipase (PLC) leading to mobilization of calcium
from intracellular stores together with the possible PKC-mediated phosphorylation could induce chloride channels opening. Both facts produce an increase in aqueous humor
inﬂow and the subsequent rise on intraocular pressure (IOP). Moreover, the increase on IOP activates TRPV4 inducing a rise on calcium intracellular concentration, which at the
same time produces the Ap4A release mainly through pannexin 1 and in lesser extent by vesicular exocytosis feeding back this process.
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duces a profound and long-lasting reduction in IOP (Martin-Gil
et al., 2012).
The mechanism by which P2Y2 receptor stimulated by Ap4A
produces it effect seems to be a combination of several cellular
mechanisms. It has been observed in non-pigmented ciliary
epithelial cells that the activation of the P2Y2 receptor increases the
trafﬁc of aquaporin 1 (AQ1) from intracellular stores to the plasma
membrane (Martin-Gil and Pintor, 2010; Pintor, 2010). This effect
should be a consequence of the activation of the canonical pathway,
which triggers PKC activation (Guzman-Aranguez and Pintor,
2012). The mobilization of AQ1 triggered by Ap4A, was able to
mobilize AQP1 which was time dependent, themaximal expression
in the cell membranes occurring 1 h after the application of the
dinucleotide and returning to initial values in two hours' time
(Martin-Gil and Pintor, 2010). Unpublished results performed in
our laboratory, demonstrated that apart from AQ1 trafﬁcking there
was a net ﬂow of Cl from ciliary epithelial cells, this ion being
responsible for aqueous humour secretion. In other cellular models,
achondroplastic chondrocytes, the effect of Ap4A was virtually
identical. In this model, diadenosine tetraphosphate was also
facilitating the efﬂux of chloride from these cells (Huete et al.,
2011). Therefore, it seems that there is a coordinated action trig-
gered by the P2Y2 receptor after the stimulation by Ap4A that
produces a mobilization of AQ1 towards the membrane and an
increase in the Cl efﬂux, which altogether, would be responsible
for the P2Y2 mediated elevation of IOP (Fig. 10).Please cite this article in press as: Carracedo, G., et al., The role of dinucle
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There are no studies in the literature investigating the role of
dinucleotides in the lens. Therefore, a possibility is to suggest some
of the possible effects, just by checking on the P2 receptors present
in the lens that are suitable for stimulation by dinucleoside
polyphosphates.
The lens epithelium can respond to the changes in the con-
centration of dinucleotides found in the aqueous humour as pre-
viously described. The identiﬁcation of P2Y receptors (P2Y1 and
P2Y2) by RT-PCR and in situ hybridization in the lens has been
described (Cowlen et al., 2003; Hu et al., 2008; Merriman-Smith
et al., 1998). Because Ap4A is most representative of the dinucleo-
tide in the aqueous humour, and its ability is known to stimulate
both receptors, changes in Ap4A concentration could alter intra-
cellular Ca2þ concentration in cortical lens ﬁbers. Moreover, cal-
cium mobilization in the lens could modulate the activity of
different Kþ channels (Rhodes et al., 2003), which will determine
the membrane potential of the lens, and subsequently the Cl
channels that contribute to lens volume regulation and trans-
parency (Valverde et al., 1992).
2.2.4. Neuroprotective role in the ciliary body
The neuroprotective effect of Ap4A is closely related to the fact
that this dinucleotide is stored in synaptic vesicles together with
different classical neurotransmitters (Miras-Portugal et al., 1998). In
this sense, apart from its roles inhibiting the epileptiform activity
and synaptic potentials in the hippocampus (Klishin et al., 1994;
Ross et al., 1999) and inhibition of glutamate release in the stria-
tum (Oaknin et al., 2001) or the stimulation of locus coeruleus,oside polyphosphates on the ocular surface and other eye structures,
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present interesting properties protecting the nervous system from
damage.
Studies performed at the CNS have demonstrated that Ap4A can
give protection from the neurodegeneration induced by methyl-
amphetamine either in In vitro or in In vivo experiments (Harvey
et al., 2009). This protective effect also exists when cerebral
ischemia exists or when sympathetic terminals are chemically
damaged by means of 6-OH-dopamine (Wang et al., 2003).
Neurodegenerative diseases like Alzheimer's disease or Parkin-
son's, can affect, of course the CNS, but they also alter the auto-
nomic nervous system causing dysautonomia, this being important
in the eye since it can raise IOP augmenting the prevalence of
glaucoma in patients suffering from these two pathologies which
are signiﬁcantly higher than in the normal population (Bayer et al.,
2002). Many patients with Parkinson's disease have a signiﬁcant
loss of their visual ﬁeld which is typical of the development of
glaucoma (Yenice et al., 2008).
Since the presence of diadenosine tetraphosphate has been
demonstrated in the aqueous humour both in humans and animal
models (Castany et al., 2011; Pintor et al., 2003), the possibility of
this dinucleotide acting in the sameway as in the CNS is a matter of
interest. In this sense, it has been demonstrated in New Zealand
white rabbits that the chemical destruction by means of 6-OH-
dopamine or reserpine, clearly eliminates sympathetic terminals
altering the control of IOP among other processes. In this sense,
subconjunctival injections of 6-OHDA cause sympatholysis with a
sharp fall in IOP. Also a clear miosis has been observed as a
consequence of the chemical denervation together with a loss of
ocular sympathetic reﬂexes and a sharp reduction in the labelling of
intraocular sympathetic neurons (Hoyle and Pintor, 2010).
On a preliminary study on the possible effect of diadenosine
tetraphosphate protecting the nervous system, the application of
100 mMAp4A three days before the treatment with 6-OH dopamine
or reserpine and 2 more days after the chemical denervation,
preserved the sympathetic terminals present in the ciliary body
from chemical denervation and therefore rabbits IOP did not fall as
happens in the absence of the dinucleotide (Hoyle and Pintor,
2010). This effect is quite unusual, since the nucleotide ATP and
the nucleoside adenosine were totally unable to mimic Ap4A pro-
tective effect. Although adenosine acts via its own receptors, ATP
and Ap4A should use common P2 receptors (Pintor and Miras-
Portugal, 1995b). P2Y2 receptors have been described in the
ciliary body in New Zealand white rabbits (Martin-Gil et al., 2012).
Nevertheless, and according to its pharmacology, both ATP and
Ap4A should activate this receptor the ﬁnal effect being the same,
which is not the case. It could be the case that a selective receptor
for diadenosine polyphosphates and not activated by ATP could be
the one producing this protective effect (Pintor and Miras-Portugal,
1995a, 2000). To date this is the only evidence for a selective
dinucleotide receptor in the eye and more research is needed to
conﬁrm its real existence.
The way the dinucleotide Ap4A is protecting the ciliary body
against 6-OH dopamine has not been clariﬁed to date. One possi-
bility is that the P2 receptor activated by Ap4A may induce the
down-regulation (internalization) of the monomine transporter.
This has been described for other transporters such as the dopa-
mine transporter in the CNS (Xie and Miller, 2009). The involve-
ment of P2Y receptors inhibiting transporters has already been
described and moreover, this process has been shown to occur via
protein kinase C-dependent mechanism (Sen et al., 1993). An
alternative possibility is that Ap4A stimulates a receptor connected
to protection by limiting the negative effect of excessive reactive
oxygen species. It could be the case that Ap4A may have an indirect
effect protecting neurons against free radical damage. MelatoninPlease cite this article in press as: Carracedo, G., et al., The role of dinucle
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2001), and it is an intriguing possibility that Ap4A can stimulate
the release of melatonin from intraocular epithelium where it is
synthesised (Zmijewski et al., 2009).
2.3. Dinucleoside polyphosphates in the posterior pole
2.3.1. Dinucleotide effect on retinal detachment
One of the eye parts in which the research is weaker concerning
dinucleoside polyphosphates is the retina. The presence of P2 re-
ceptors that might be stimulated by dinucleotides is broad in
retinal cells, nevertheless, apart from the dinucleotide effect on
retinal detachments, it is only possible to establish speculations
about the actions of these compounds by means of such receptors.
Some therapeutic actions involve dinucleoside polyphosphates
in relevant pathological states of the retina such as retinal
detachment. Receptors for nucleotides in the retinal pigmented
epithelium were described in the late 90's (Peterson et al., 1997;
Sullivan et al., 1997), mostly P2Y2 suitable for dinucleotide activa-
tion (Guzman-Aranguez et al., 2011; Guzman-Aranguez and Pintor,
2012). This fact made some researchers develop studies on animal
models which were submitted to retinal detachment. In these
models it was possible to demonstrate that some dinucleoside
polyphosphates such as deoxycytidine tetraphospho uridine, also
known as INS37217, or denufosol, was able to re-absorb the bleb
between RPE and the neural retina in a very efﬁcient way (Yerxa
et al., 2002b). This dinucleotide (INS37217), which is a P2Y2
agonist, signiﬁcantly enhanced subretinal ﬂuid reabsorption when
compared with vehicle controls (Maminishkis et al., 2002; Meyer
et al., 2002; Nour et al., 2003). One positive aspect is that
INS37217 had no adverse effects on electroretinograms. In this
sense, both scotopic and photopic ERG amplitudes and latency
parameters remained stable when INS37217 was applied, this being
a beneﬁcial aspect to take into account (Meyer et al., 2002). Other
authors, on the contrary, indicate that subretinal injections of saline
containing INS37217 signiﬁcantly increased rod and cone ERG of
normal and rds (±) mice at 1 and 10 days post-injections, when
compared with injection of saline alone (Nour et al., 2003). These
experiments indicate that the dinucleotide INS37217 enhances ERG
recovery probably by reducing retinal folding permitting re-
attachment.
It is important to note that the experiments performed with this
dinucleotide demonstrated an increase in ﬂuid absorption not only
in animal models but also in freshly isolated bovine and fetal human
RPE monolayers (Maminishkis et al., 2002), and therefore the mol-
ecules would be a good candidate for the treatment of retinal de-
tachments. Nevertheless, it is not all good news. There are two main
handicaps in these studies; ﬁrst, denufosol in some cases, to develop
its action, needs to be used at high concentrations (around 1 mM)
(Meyer et al., 2002), which may produce the re-absorption process
but presumably also the activation ofmany other P2 receptors due to
the high concentrations of the dinucleotide. Second, in order to act it
is necessary to be applied by means of intravitreal injections
(Maminishkis et al., 2002; Meyer et al., 2002; Nour et al., 2003).
2.3.2. Presence in other posterior structures
As discussed above, diadenosine polyphosphates and other
nucleotides could activate metabotropic and ionotropic receptors
described in mammalian retina (Cowlen et al., 2003; Franke et al.,
2005; Fries et al., 2004; Greenwood et al., 1997; Kaneda et al.,
2008; Notomi et al., 2011; Peterson et al., 1997; Pintor et al.,
2004b; Puthussery and Fletcher, 2004, 2007; Shigematsu et al.,
2007; Ward et al., 2008; Wheeler-Schilling et al., 2000, 2001).
Numerous studies indicate a wide distribution of purinergic re-
ceptors throughout the different layers of retina. It can be suggestedoside polyphosphates on the ocular surface and other eye structures,
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tential physiological roles.
The activation of purinergic receptors through nucleotides and
dinucleotides, such as diadenosine polyphosphates, may be impli-
cated in embryo development and retinal precursor cell prolifera-
tion due to the implication of P2 receptors described in early neural
retina (Sugioka et al., 1999). Transcriptional regulation changes of
these receptors during the development clearly indicate the rele-
vant endogenous nucleotides participation.
Although both P2X and P2Y receptors have been observed in
several neuronal populations including photoreceptors, amacrine
and ganglion cells, recent studies suggest the implication of P2X
receptors in the modulation of visual neurotransmission activity
(Kaneda et al., 2008; Puthussery and Fletcher, 2004, 2007;
Puthussery et al., 2006; Vessey and Fletcher, 2012) and the pre-
sumable involvement of diadenosine polyphosphates. Moreover, it
could be contributing to the shedding of photoreceptor outer seg-
ments via P2Y receptors.
Furthermore, nucleotides serve as vasoactive signals in the
pericyte-containing microvasculature of the retina. Different
studies suggest nucleotides-induced increase in calcium levels and
cellular contraction (Kawamura et al., 2003; Sugiyama et al., 2006).
In this sense, dinucleotides polyphosphates may contribute to
regulate capillary function in retina. Moreover, P2X7 receptor
activation triggered pericyte apoptosis that may be improved by
P2Y4 inhibition (Sugiyama et al., 2006). For that action, ATP, dia-
denosine polyphosphates and other nucleotides balance have
particular relevance in the environmental extracellular modulation
and the concomitant activation of P2 receptors. Apart from peri-
cytes it is also important to take into consideration the contribution
of choroid in the retinal circulation. In this sense, it is important to
consider the role of nucleotides and dinucleotides due to their
relevant participation in vasoactive signals in the retinal vascula-
ture including choriocapillaris and choroidal vasculature. Several
authors have observed ATP action modifying ionic currents leading
contractions of pericytes as previously commented (Kawamura
et al., 2003) and apoptosis processes via P2X7 receptor activation.
Moreover the dinucleotide concentration in blood should also
modify endothelial cells by means of P2Y2 receptors (Flores et al.,
1999) facilitating vasodilation and therefore changing the retinal
physiology.
Some of these functional implicationsmay possibly bemediated
by dinucleoside polyphosphates co-stored with ATP and classical
neurotransmitters. In fact, the presence of ATP and Ap4A levels
observed in stimulated retinas indicate the importance of these
molecules in neurotransmission process (Dr. Perez de Lara, per-
sonal communication).
Finally, the presence of nucleotides in retinal glial cells could be
responsible for the maintenance of homeostasis regulation for
suitable functioning of the neural retina, among others. The mo-
lecular cloning and functional characterization of different families
of ectoenzymes capable of hydrolyzing ATP, diadenosine poly-
phosphates and other nucleotides point to the relevance of this
complex balance maintenance.
Extracellular concentration of dinucleotides or their metabolites
at retinal level are regulated by ecto-nucleotidases, nucleoside
transporters and enzymes of adenosine metabolism. Neural retina,
but also retinal pigment epithelium, expresses ecto-enzymes
including NPP1 (described in Müller cells, the major glial compo-
nent of the retina), NTPDase 2 (also expressed in Müller cells) and
eN/5NTE (located on photoreceptors, Müller cells and retinal
pigment epithelium) (Iandiev et al., 2007; Reigada et al., 2006;
Takizawa, 1998; Wurm et al., 2010).
Again, retinal structures possess several purinergic receptors
and thus, the response of their cells depends on dinucleotides andPlease cite this article in press as: Carracedo, G., et al., The role of dinucle
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2008). Furthermore, adenosine effects in retina may be regulated
by equilibrative (ENT1 and ENT2) and concentrative nucleoside
transporters (CNT2 and CNT3) as well as adenosine deaminase 2
(ADA2) (Akanuma et al., 2013; dos Santos-Rodrigues et al., 2011;
Elsherbiny et al., 2013; Nagase et al., 2006). In fact, patients with
diabetes express a high level of ADA2, which impaired the anti-
inﬂammatory activity of adenosine at retina level (Elsherbiny
et al., 2013).
Other relevant aspect that needs to be taken into consideration
is the possible role of dinucleoside polyphosphates ameliorating
retinal neuropathy. On the one hand, it has been described that the
activation of some P2 receptors such as P2Y2 (Nour et al., 2003;
Maminishkis et al., 2002) and P2Y13 (Perez-Sen et al., 2015) may
be involved in neuroprotection processes mediated by MAPK
pathway in the retina. Moreover, the exacerbated activity of ecto-
enzymes (NPPs) in pathological conditions may also contribute to
this process, but more work is necessary to conﬁrm the implication
of ectonucleotidases on retinal impairment.
3. Conclusions and future directions
The participation of dinucleoside polyphosphates in ocular
physiology opens the possibility of using these compounds for the
treatment of relevant eye pathologies. Beginning with the ocular
surface to the retina, the application of these dinucleotides may
help to improve several processes, which may be altered in the
pathology.
Dry eye is treated in some countries such as Japan and South
Korea by means of the dinucleotides Up4U. This nucleotide can
clearly increase tear secretion, both the aqueous and the mucin
components. This is the only dinucleoside polyphosphate that is
commercially available as a pharmaceutical compound. None of the
others have moved to a clinical study as a previous step to
commercialization. Nonetheless, many of the actions, mostly dia-
denosine polyphosphates do present very promising aspects from a
therapeutic point of view as has been commented.
The advance in research needs some changes in order to be
more successful in the search for dinucleotides as therapeutic
agents. On the one hand, most of the compounds tested in their
ability to counteract some of the pathological situations already
described, have the characteristics of being fully degradable by
ectonucleotidases (NPPs) therefore limiting their real effects
(Asensio et al., 2007). In this sense it would be of interest to develop
some compounds resistant to the hydrolysis. The best way to pro-
tect these compounds from cleavage consists of substituting the
ester bonds between the phosphates by methylene or amino
groups. This has been done by some researchers (Biriukov et al.,
1987) although it has not been tested if they improve the efﬁcacy
of the dinucleotides already tested in the eye (Chan et al., 1997).
This is an area of interest that deserves work because it may indi-
cate that lower concentrations can produce the same or even better
effects. On the other hand, it is very probable that by introducing
such changes it may be possible to synthesize dinucleoside poly-
phosphates to becomemore selective to some receptors. Selectivity
would permit us to reach speciﬁc targets without affecting other
processes. It is important to be aware that, for example, a dinu-
cleotide such as Ap4A can act on several P2 receptors (Pintor et al.,
1996; Pintor and Miras-Portugal, 1995b, 2000), and therefore it
would be able to stimulate all of them while it could be the case
that only a particular subtype is needed to be activated. In this
sense, hydrolysis resistant and selective dinucleotides are neces-
sary to produce better, more selective and long-term effects.
Another important aspect that deserves attention is the delivery
of the dinucleotides to internal parts of the eye. It is clear thatoside polyphosphates on the ocular surface and other eye structures,
reteyeres.2016.07.001
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the given dinucleotides. Nonetheless, it is important to note that
intraocular actions implies the delivery through the cornea, and
this may reduce the availability of the dinucleotides in the aqueous
humour and in the inner structures. The use of carriers such as li-
posomes is a possibility, although to our knowledge, no one has
tested dinucleotides with vehicles like those. Interestingly, it has
been indicated that some dinucleotides such as Ap4A, when applied
on the ocular surface can temporarily open corneal epithelial tight-
junctions (Loma et al., 2015b) facilitating the entry of compounds
within the eye (Loma et al., 2015a). This means that those actions
carried out by dinucleoside polyphosphates in the inner eye may be
enhanced if the application of the dinucleotide, Ap4A, is applied
two hours previously. It is necessary to investigate this since, if the
entry of the dinucleotide is improved it is possible that it may reach
very deep areas of the eye.
In conclusion, dinucleoside polyphosphates are involved in a
multitude of physiological processes which are relevant for the
correct functioning of the eye. There are many promising per-
spectives using some of these compounds from a therapeutic point
of view, however it is clear that new synthetic analogues of these
dinucleotides are necessary to fully develop a battery of pharma-
ceutical compounds suitable for ocular therapy.
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